← 產業報告目錄

Pharmaceutical Drug Delivery Market By Administration Route (Oral, Injectable, Topical, Ocular, Nasal, Transmucosal & Implantable, Pulmonary, Transdermal Patch), Application (Cancer, Diabetes, Cardiovascular), Facility of Use - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-05-14頁數 1284報告編號 MD3871

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The pharmaceutical drug delivery market is projected to grow from USD 2,152.45 billion in 2026 to USD 2,922.82 billion by 2031, at a CAGR of 6.3% during the forecast period. The market is growing at a healthy pace due to an increase in chronic diseases globally and the use of biologics, biosimilars, and advanced therapies. The shift towards patient-friendly and self-administration therapies is facilitating the adoption of new injectable, inhalation, transdermal, and targeted delivery systems in the developed and emerging economies. The trend of prescribing large-molecule drugs has led to a rise in investments in cutting-edge delivery vehicles such as lipid nanoparticles, long-acting depots, controlled-release formulations, and wearable injectors. Meanwhile, digital and connected drug-device technologies are facilitating greater treatment precision, patient adherence, and remote monitoring of patients. Market growth is enabled by innovations in device engineering, automation, and biologic stabilization. Nevertheless, the industry is still grappling with issues such as high costs of developing and manufacturing products, more stringent global regulatory requirements, and complexities related to the supply chain and sterility. However, continuous innovation and a significant move towards home-based and patient-centric care are still fueling strong growth in the global pharmaceutical drug delivery market. “Injectable drug delivery segment accounted for the largest market share in 2025” Based on route of administration, the injectable drug delivery segment dominates the pharmaceutical drug delivery market at a global level. This is linked to the growing incidence of chronic diseases both in developed and developing countries, as well as the worldwide trend of using biologics, biosimilars, peptides, oligonucleotides, and cell & gene therapies that are only parenterally administered due to low oral bioavailability and degradation issues. Moreover, innovations in prefilled syringes, autoinjectors, wearable injectors, needles, free jet injectors, subcutaneous rapid infusion systems, and micro/nanocarrier platforms have changed the injectable drug delivery landscape completely by making drug delivery safer, more comfortable, and easier to use. These technological advances have led to a huge increase in self-administration out of the hospital and have pushed the penetration of injectable drug delivery systems in the global market much quicker. “Hospitals segment captured the largest share of the market for formulations in 2025” The hospital segment accounted for the largest share of the global pharmaceutical drug delivery market in 2025. Hospitals are supported by advanced infrastructure, trained clinical staff, and have the capability to manage biologics, monoclonal antibodies, radiopharmaceuticals, and other specialty treatments that require precise dosing and continuous monitoring. They offer the perfect setting for such treatments. An increased usage of large-molecule drugs has contributed to a rise in demand for sophisticated hospital-based delivery systems such as infusion pumps, long-acting injectables, nanoparticle formulations, and depot implants. Such innovative drug delivery devices and methods assist in keeping the drugs stable, ensure accurate administration, and thereby, significantly enhance the effectiveness of therapies. Worldwide regulatory bodies keep safety, device, drug compatibility, and human factor performance at the top of their priorities when it comes to hospital-administered delivery platforms. Therefore, to meet the regulations, the companies have to reinforce design, testing, and quality controls. Hospitals continue to be the most important Facility of Use in the global drug delivery landscape, as they handle more and more cases that need advanced parenteral and device-assisted therapies. “In 2025, North America dominated the pharmaceutical drug delivery market” North America held the largest market share in 2025, which can be attributed to an advanced healthcare infrastructure, strong uptake of biologics and specialty medicines, and extensive R&D activity. Autoinjectors, prefilled syringes, wearable injectors, and connected drug, device platforms are adopted as a result of high chronic disease prevalence and a growing demand for self-administration in the region. The area is home to major pharmaceutical and drug, device companies that are constantly looking for new formulation technologies, high-precision injection systems, nanoparticle-based platforms, and controlled-release mechanisms. The regulatory pathways, especially the US FDA’s ones, are very supportive, and thus, combination products and biologic delivery systems help to maintain North America’s dominant position. Besides that, strong biotech clusters, research institutions, and CDMOs are also helping to create a highly innovative drug delivery ecosystem. Breakdown of supply-side primary interviews: • By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%) • By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%) • By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%) Breakdown of demand-side primary interviews: •By End User: Hospitals (59%), Ambulatory Surgery Centers/Clinics (16%), Home Care Settings (15%), Diagnostic Centers (6%), and Other Facilities of Use (4%) •By Designation: Physicians (47%), Hospital Directors and Managers (22%), Home-Care & Ambulatory Care Professionals (15%), and Other Designations (16%) •By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and Middle East & Africa (15%) Research Coverage This report studies the pharmaceutical drug delivery market based on route of administration, application, facility of use, and region. The report also studies factors (drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions). Reasons to Buy the Report The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies for strengthening their market presence. This report provides insights into the following pointers:  Analysis of Key Drivers, Restraints, Opportunities, Challenges  Market Penetration: Comprehensive information on the product portfolios offered by the top players in the pharmaceutical drug delivery market  Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the pharmaceutical drug delivery market  Market Development: Comprehensive information on lucrative emerging regions  Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pharmaceutical drug delivery market  Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players
目錄 Table of Contents
1 INTRODUCTION 105 1.1 STUDY OBJECTIVES 105 1.2 MARKET DEFINITION 105 1.3 STUDY SCOPE 106 1.3.1 MARKETS COVERED 106 1.3.2 INCLUSIONS & EXCLUSIONS 107 1.3.3 YEARS CONSIDERED 108 1.3.4 CURRENCY CONSIDERED 108 1.4 MAJOR STAKEHOLDERS 109 1.5 SUMMARY OF CHANGES 109 2 EXECUTIVE SUMMARY 111 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 111 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 112 2.3 DISRUPTIVE TRENDS IN PHARMACEUTICAL DRUG DELIVERY MARKET 113 2.4 HIGH-GROWTH SEGMENTS 114 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 115 3 PREMIUM INSIGHTS 116 3.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW 116 3.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION & COUNTRY (2025) 117 3.3 PHARMACEUTICAL DRUG DELIVERY MARKET: REGIONAL MIX 118 3.4 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 118 3.5 PHARMACEUTICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 119 4 MARKET OVERVIEW 120 4.1 INTRODUCTION 120 4.2 MARKET DYNAMICS 120 4.2.1 DRIVERS 121 4.2.1.1 Advancements in drug delivery technologies 121 4.2.1.2 Rising burden of chronic diseases and aging population 122 4.2.1.3 Growing adoption of biologics and biosimilars 125 4.2.1.4 Growing emphasis on patient convenience 126 4.2.1.5 Increasing investments in pharmaceutical R&D 127 4.2.2 RESTRAINTS 127 4.2.2.1 Infections associated with needlestick injuries 127 4.2.2.2 Stringent government regulations 128   4.2.3 OPPORTUNITIES 129 4.2.3.1 Geographic expansion into emerging markets 129 4.2.3.2 Integration with digital health & remote monitoring 129 4.2.4 CHALLENGES 130 4.2.4.1 Pricing pressure by governing bodies 130 4.3 UNMET NEEDS & WHITE SPACES 130 4.3.1 UNMET NEEDS IN PHARMACEUTICAL DRUG DELIVERY MARKET 130 4.3.2 WHITE SPACE OPPORTUNITIES 131 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 132 4.4.1 INTERCONNECTED MARKETS 132 4.4.2 CROSS-SECTOR OPPORTUNITIES 133 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 133 4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 133 5 INDUSTRY TRENDS 135 5.1 PORTER’S FIVE FORCES ANALYSIS 135 5.1.1 THREAT OF NEW ENTRANTS 136 5.1.2 THREAT OF SUBSTITUTES 136 5.1.3 BARGAINING POWER OF SUPPLIERS 137 5.1.4 BARGAINING POWER OF BUYERS 137 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 137 5.2 MACROECONOMIC INDICATORS 138 5.2.1 INTRODUCTION 138 5.2.2 GDP TRENDS & FORECAST 138 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 139 5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL DRUG DELIVERY INDUSTRY 140 5.3 VALUE CHAIN ANALYSIS 140 5.4 ECOSYSTEM ANALYSIS 142 5.5 PRICING ANALYSIS 143 5.5.1 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025 144 5.5.1.1 Average selling price trend of injectable drug delivery products, by key player, 2023−2025 144 5.5.1.2 Average selling price trend of oral drug delivery products, by key player, 2023−2025 145 5.5.1.3 Average selling price trend of topical drug delivery products, by key player, 2023−2025 145 5.5.2 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY REGION, 2023–2025 146 5.5.2.1 Average selling price trend of injectable drug delivery products, by region, 2023−2025 146 5.5.2.2 Average selling price trend of oral drug delivery products, by region, 2023−2025 147 5.5.2.3 Average selling price trend of topical drug delivery products, by region, 2023−2025 147 5.5.2.4 Average selling price trend of pulmonary drug delivery products, by region, 2023−2025 147 5.5.2.5 Average selling price trend of ocular drug delivery products, by region, 2023−2025 148 5.5.2.6 Average selling price trend of nasal drug delivery products, by region, 2023−2025 148 5.6 TRADE ANALYSIS 148 5.6.1 TRADE DATA FOR HS CODE 3004 149 5.6.1.1 Import data for HS Code 3004 149 5.6.1.2 Export data for HS Code 3004 150 5.6.2 TRADE DATA FOR HS CODE 9018 150 5.6.2.1 Import data for HS Code 9018 150 5.6.2.2 Export data for HS Code 9018 151 5.7 KEY CONFERENCES & EVENTS, 2026–2027 151 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 152 5.9 INVESTMENT & FUNDING SCENARIO 153 5.10 REIMBURSEMENT ANALYSIS 154 5.11 PIPELINE ANALYSIS 155 5.12 SUCCESS STORIES & REAL-WORLD APPLICATIONS 166 5.12.1 MEDTRONIC – INSULIN PUMP DRUG DELIVERY SYSTEM 166 5.12.2 YPSOMED – SMARTPILOT CONNECTED DRUG DELIVERY 167 5.12.3 ENABLE INJECTIONS – ENFUSE CLINICAL PERFORMANCE 168 5.13 IMPACT OF US TARIFFS—PHARMACEUTICAL DRUG DELIVERY MARKET 168 5.13.1 INTRODUCTION 168 5.13.2 KEY TARIFF RATES 169 5.13.3 PRICE IMPACT ANALYSIS 170 5.13.4 IMPACT ON COUNTRIES/REGIONS 171 5.13.5 IMPACT ON END-USE INDUSTRIES 173 5.13.5.1 Impact on end-use industries: formulations 173 5.13.5.1.1 Hospitals 173 5.13.5.1.2 Ambulatory surgical centers/clinics 173 5.13.5.1.3 Home care settings 173 5.13.5.2 Impact on end-use industries: devices 173 5.13.5.2.1 Pharmaceutical companies 173 5.13.5.2.2 Biotechnology companies 174 5.13.5.2.3 Contract development and manufacturing organizations (CDMOs) & contract research organizations (CROs) 174   6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 175 6.1 TECHNOLOGY ANALYSIS 175 6.1.1 KEY EMERGING TECHNOLOGIES 175 6.1.1.1 Nanotechnology-based drug delivery 175 6.1.1.2 Smart/connected drug delivery devices 175 6.1.1.3 Needle-free injection systems and microneedle patches 176 6.1.2 COMPLEMENTARY TECHNOLOGIES 177 6.1.2.1 3D printed & personalized drug delivery 177 6.1.2.2 AI/ML in drug delivery & formulation 177 6.1.3 ADJACENT TECHNOLOGIES 178 6.1.3.1 Smart monitoring, IoT, and data-driven control 178 6.1.3.2 Cell & gene delivery vectors 178 6.2 TECHNOLOGY/PRODUCT ROADMAP 179 6.2.1 NEAR-TERM (2025–2027) 179 6.2.2 MID-TERM (2028–2030) 179 6.2.3 LONG-TERM (2030+) 180 6.3 PATENT ANALYSIS 180 6.3.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY MARKET 180 6.3.2 JURISDICTION & TOP APPLICANT ANALYSIS 181 6.4 FUTURE APPLICATIONS 183 6.4.1 PATIENT-CENTRIC DRUG DELIVERY SYSTEMS 184 6.4.2 MINIMALLY INVASIVE AND SELF-ADMINISTERED DELIVERY 184 6.4.3 LONG-ACTING AND BIOLOGIC DRUG DELIVERY SYSTEMS 184 6.4.4 DIGITAL AND AI-ENABLED DRUG DELIVERY 184 6.5 IMPACT OF AI/GENERATIVE AI ON PHARMACEUTICAL DRUG DELIVERY MARKET 184 6.5.1 INTRODUCTION 184 6.5.2 MARKET POTENTIAL IN PHARMACEUTICAL DRUG DELIVERY ECOSYSTEM 185 6.5.3 AI USE CASES 185 6.5.4 KEY COMPANIES IMPLEMENTING AI IN PHARMACEUTICAL DRUG DELIVERY MARKET 186 7 SUSTAINABILITY & REGULATORY LANDSCAPE 187 7.1 REGIONAL REGULATIONS & COMPLIANCE 187 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 187 7.1.2 INDUSTRY STANDARDS 193 7.2 SUSTAINABILITY INITIATIVES 194 7.2.1 ENERGY-EFFICIENT MANUFACTURING & CARBON REDUCTION IN PHARMACEUTICAL DRUG DELIVERY 194 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 194 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 195 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 197 8.1 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 197 8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS (DEVICES) 197 8.1.2 KEY STAKEHOLDERS IN BUYING PROCESS (FORMULATIONS) 198 8.1.3 BUYING CRITERIA 198 8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 200 8.2.1 DECISION-MAKING PROCESS 200 8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 200 8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 201 8.2.4 MARKET PROFITABILITY 202 9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 203 9.1 INTRODUCTION 204 9.2 INJECTABLE DRUG DELIVERY 205 9.2.1 DEVICES 207 9.2.1.1 Conventional injection devices 211 9.2.1.1.1 Rising incidence of chronic diseases and low cost of manufacturing to drive the market 211 9.2.1.1.2 Global Volume Analysis of Conventional Injection Devices, 2024-2031(Ten Thousand Units) 213 9.2.1.1.3 By material 215 9.2.1.1.3.1 Glass 215 9.2.1.1.3.2 Plastic 217 9.2.1.1.4 By usability 219 9.2.1.1.4.1 Reusable 219 9.2.1.1.4.2 Disposable 221 9.2.1.1.5 By type 223 9.2.1.1.5.1 Fillable syringes 223 9.2.1.1.6 Prefilled syringes 225 9.2.1.2 Self-injection devices 226 9.2.1.2.1 Global Volume Analysis of Self-Injection Devices, 2024-2031(Ten Thousand Units) 228 9.2.1.2.2 Needle-free injectors 229 9.2.1.2.3 Autoinjectors 231 9.2.1.2.4 Pen injectors 233 9.2.1.2.5 Wearable injectors 235 9.2.1.3 Other injectable devices 236 9.3 FORMULATIONS 238 9.3.1 BY TYPE 240 9.3.1.1 Conventional drug delivery formulations 240 9.3.1.2 Novel drug delivery formulations 243 9.3.1.3 long-acting injectable formulations 245 9.3.2 BY FORMULATION PACKAGING 246 9.3.2.1 Ampoules 247 9.3.2.1.1 Helps maintain the stability of drugs, thereby enhancing efficacy 247 9.3.2.2 Vials 249 9.3.2.2.1 Ability to store drug formulations for extensive periods 249 9.3.2.3 Cartridges 250 9.3.2.3.1 Offers higher dose accuracy and patient convenience 250 9.3.2.4 Bottles 251 9.3.2.4.1 Easy storage of solutions and emulsions drives demand 251 9.4 ORAL DRUG DELIVERY 252 9.4.1 SOLID ORAL DRUGS 254 9.4.1.1 Tablets 256 9.4.1.1.1 Development of mini-tablets is a key trend in this market segment 256 9.4.1.2 Capsules 258 9.4.1.2.1 Easy absorption of drugs and decreased irritation in GI tract drive use of capsules 258 9.4.1.3 Powders 259 9.4.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms 259 9.4.1.4 Granules 260 9.4.1.4.1 Increasing adoption of modified-release and pediatric-friendly formulations driving granules market growth 260 9.4.1.5 Lozenges 262 9.4.1.5.1 Prolonged drug release and localized action enhancing adoption of lozenges 262 9.4.2 LIQUID ORAL DRUGS 263 9.4.2.1 Syrups 265 9.4.2.1.1 Easy administration to patients with swallowing difficulties 265 9.4.2.2 Solutions 266 9.4.2.2.1 Geriatric and pediatric patients generally prefer solutions 266 9.4.2.3 Emulsions 268 9.4.2.3.1 Emulsions offer enhanced solubility and stability with ease of administration 268 9.4.2.4 Suspensions 269 9.4.2.4.1 Increasing demand for pediatric and geriatric-friendly formulations is driving the oral suspension market growth 269 9.4.2.5 Elixirs 270 9.4.2.5.1 Elixirs are a preferred choice for the pediatric population 270 9.4.3 SEMI-SOLID ORAL DRUGS 272 9.4.3.1 Gels 273 9.4.3.1.1 Gels are used for controlled drug release 273 9.4.3.2 Pastes 274 9.4.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis 274 9.5 TOPICAL DRUG DELIVERY 276 9.5.1 SEMI-SOLID FORMULATIONS 278 9.5.1.1 Ointments 281 9.5.1.1.1 Ointments are widely used in analgesic indications 281 9.5.1.2 Creams 283 9.5.1.2.1 Creams are either water-in-oil or oil-in-water emulsions 283 9.5.1.3 Lotions 285 9.5.1.3.1 Easy administration of lotions to drive demand among end users 285 9.5.1.4 Gels 287 9.5.1.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels 287 9.5.1.5 Pastes 289 9.5.1.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation 289 9.5.2 LIQUID FORMULATIONS 290 9.5.2.1 Suspensions 292 9.5.2.1.1 Higher rate of bioavailability and controlled onset of action to drive market 292 9.5.2.2 Emulsions 294 9.5.2.2.1 Improved spreadability, stability, and controlled release of active ingredients 294 9.5.2.3 Solutions 295 9.5.2.3.1 Uniform & rapid drug delivery to boost demand 295 9.5.3 SOLID FORMULATIONS 297 9.5.3.1 Powders 299 9.5.3.1.1 Powders have a very fine particle size that covers a large surface area per unit weight 299 9.5.3.2 Suppositories 300 9.5.3.2.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug 300 9.5.4 FILMS 302 9.5.4.1 Next-generation advancements to boost demand 302 9.5.5 TRANSDERMAL FORMULATIONS 304 9.5.5.1 Transdermal patches 306 9.5.5.1.1 Transdermal patches prevent premature metabolization of drugs through the liver 306 9.5.6 TRANSDERMAL GELS 308 9.5.6.1 Rapid release of drugs to fuel uptake 308 9.5.7 TRANSDERMAL SPRAYS 309 9.5.7.1 Targeted approach to boost demand 309   9.6 OCULAR DRUG DELIVERY 311 9.6.1 LIQUID FORMULATIONS 313 9.6.1.1 Eye drops 314 9.6.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth 314 9.6.1.2 Liquid sprays 316 9.6.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops 316 9.6.2 SEMI-SOLID FORMULATIONS 317 9.6.2.1 Gels 319 9.6.2.1.1 High viscosity of drugs, prolonged drug release, and ease of drug administration contribute to market growth 319 9.6.2.2 Eye ointments 320 9.6.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug 320 9.6.3 OCULAR DEVICES 321 9.6.3.1 Drug-coated contact lenses 323 9.6.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses 323 9.6.3.2 Ocular inserts 325 9.6.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye 325 9.7 PULMONARY DRUG DELIVERY 327 9.7.1 PULMONARY DRUG DELIVERY DEVICE 329 9.7.1.1 Metered-dose Inhalers 330 9.7.1.2 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath 330 9.7.1.2.1 Global Volume Analysis of Metered Dose Inhalers, By Region, 2024–2031 (Ten thousand units) 331 9.7.1.3 Dry Powder Inhalers 332 9.7.1.3.1 Dry powder inhaler formulations are chemically more stable than their counterparts 332 9.7.1.3.2 Global Volume Analysis of Dry Powder Inhalers, By Region, 2024–2031 (Ten thousand units) 333 9.7.1.4 Nebulizers 334 9.7.1.4.1 Global Volume Analysis of Nebulizers, By Region, 2024–2031 (Ten thousand units) 335 9.7.1.4.2 Jet nebulizers 337 9.7.1.4.2.1 Jet nebulizers account for the largest share of the nebulizers market 337 9.7.1.4.3 Ultrasonic nebulizers 338 9.7.1.4.3.1 Ultrasonic nebulizers are easy to use and comfortable to handle 338 9.7.1.4.4 Soft mist nebulizers 339 9.7.1.4.4.1 Soft mist nebulizers are preferred for the treatment of severe COPD 339 9.7.2 PULMONARY DRUG DELIVERY FORMULATION 341 9.7.2.1 Suspension Aerosol 342 9.7.2.2 Suspension Aerosols Enable Delivery of Insoluble Drug Formulations 342 9.7.2.3 Solution Aerosol 343 9.7.2.3.1 Solution Aerosols Support Uniform Drug Distribution and Formulation Flexibility 343 9.7.3 DRY POWDER FORMULATIONS 344 9.8 NASAL DRUG DELIVERY 346 9.8.1 NASAL DROPS & LIQUIDS 348 9.8.1.1 Nasal drops are considered more efficient than nasal sprays 348 9.8.2 NASAL SPRAYS 349 9.8.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing 349 9.8.3 NASAL POWDERS 351 9.8.3.1 Absence of preservatives and superior stability of formulations are some advantages associated with nasal powders 351 9.9 TRANSMUCOSAL DRUG DELIVERY 352 9.9.1 ORAL FORMULATIONS 354 9.9.1.1 Buccal drug delivery 356 9.9.1.1.1 Buccal drug delivery system is suitable for local and systemic therapies 356 9.9.1.2 Sublingual drug delivery 357 9.9.1.2.1 Higher rate of drug absorption compared to oral route drives adoption 357 9.9.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES 359 9.9.2.1 Rectal transmucosal drug delivery 360 9.9.2.1.1 Enhanced bioavailability and bypassing first-pass metabolism 360 9.9.2.2 Vaginal transmucosal drug delivery 362 9.9.2.2.1 Higher permeability and direct access to target systems drive adoption 362 9.10 IMPLANTABLE DRUG DELIVERY 363 9.10.1 ACTIVE IMPLANTABLE DRUG DELIVERY 365 9.10.1.1 Active implantable devices are used for diagnostic monitoring, body fluid transportation, and ionizing radiation 365 9.10.2 PASSIVE IMPLANTABLE DRUG DELIVERY 366 9.10.2.1 Passive implantable drug delivery systems offer a means to achieve targeted drug delivery 366 9.11 OTIC DRUG DELIVERY 368 9.11.1 EAR DROPS 369 9.11.1.1 Increasing prevalence of ear infections and demand for localized treatment are driving ear drops segment growth 369 9.11.2 OTIC SPRAYS 371 9.11.2.1 Growing demand for uniform drug distribution and improved patient convenience driving adoption 371 10 PHARMACEUTICAL DRUG DELIVERY, BY APPLICATION 373 10.1 INTRODUCTION 374 10.2 INJECTABLE DRUG DELIVERY 374 10.2.1 METABOLIC DISORDERS (DIABETES, OBESITY) 377 10.2.1.1 Rising burden of diabetes and obesity driving strong adoption of injectable drug delivery 377 10.2.2 CANCER 378 10.2.2.1 Rising prevalence of cancer and growing availability of therapeutics to drive market 378 10.2.3 IMMUNOLOGICAL & AUTOIMMUNE DISEASES 380 10.2.3.1 Increased focus on early-stage diagnosis and treatment to propel segment growth 380 10.2.4 INFECTIOUS DISEASES 381 10.2.4.1 Increasing use of liposomes to aid segment growth 381 10.2.5 OTHER INJECTABLE DRUG DELIVERY APPLICATIONS 383 10.3 ORAL DRUG DELIVERY 385 10.3.1 CARDIOVASCULAR DISEASES 387 10.3.1.1 High prevalence of CVDs and widespread use of oral therapies drive market 387 10.3.2 METABOLIC DISORDERS (DIABETES, OBESITY) 388 10.3.2.1 Growing preference for self-injection devices over traditional syringes to augment market growth 388 10.3.3 CNS DISORDERS 390 10.3.3.1 Chronic nature of CNS disorders and long-term therapy needs driving oral drug delivery adoption 390 10.3.4 INFECTIOUS DISEASES 391 10.3.4.1 High global infection burden and outpatient treatment trends driving oral drug delivery adoption 391 10.3.5 ONCOLOGY (ORAL THERAPIES) 393 10.3.5.1 Shift toward targeted therapies and at-home treatment driving oral drug delivery in oncology 393 10.3.6 OTHER ORAL DRUG DELIVERY APPLICATIONS 395 10.4 TOPICAL DRUG DELIVERY 397 10.4.1 DERMATOLOGICAL DISORDERS 399 10.4.1.1 High prevalence of skin disorders driving strong demand for topical drug delivery 399 10.4.2 PAIN MANAGEMENT 401 10.4.2.1 Localized relief and reduced systemic side-effects driving topical drug delivery in pain management 401 10.4.3 WOUND CARE 402 10.4.3.1 Rising incidence of chronic wounds and surgical procedures driving topical drug delivery in wound care 402   10.5 OCULAR DRUG DELIVERY 403 10.5.1 RETINAL DISORDERS 405 10.5.1.1 Rising prevalence of retinal diseases and biologics adoption driving growth in the retinal disorders segment 405 10.5.2 GLAUCOMA 407 10.5.2.1 High prevalence and lifelong therapy requirements driving ocular drug delivery in glaucoma 407 10.5.3 EYE INFECTIOUS DISEASES 408 10.5.3.1 High incidence of ocular infections and need for rapid localized therapy driving eye infectious diseases segment 408 10.5.4 OTHER OCULAR DRUG DELIVERY APPLICATIONS 410 10.6 PULMONARY DRUG DELIVERY 411 10.6.1 ASTHMA 413 10.6.1.1 High global asthma prevalence and lifelong inhalation therapy driving pulmonary drug delivery demand 413 10.6.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 415 10.6.2.1 Chronic disease burden and high reliance on inhalation therapies driving pulmonary drug delivery in COPD 415 10.6.3 PULMONARY INFECTIONS 416 10.6.3.1 High burden of respiratory infections and need for rapid drug action driving pulmonary drug delivery in pulmonary infections 416 10.6.4 OTHER PULMONARY DRUG DELIVERY APPLICATIONS 417 10.7 NASAL DRUG DELIVERY 419 10.7.1 ALLERGIC RHINITIS 420 10.7.1.1 High prevalence of allergic conditions driving nasal drug delivery in allergic rhinitis 420 10.7.2 SINUSITIS 422 10.7.2.1 High prevalence of sinus infections and need for targeted therapy driving nasal drug delivery in sinusitis 422 10.7.3 OTHER NASAL DRUG DELIVERY APPLICATIONS 423 10.8 TRANSMUCOSAL DRUG DELIVERY 424 10.8.1 PAIN MANAGEMENT 426 10.8.1.1 Rapid onset and improved patient compliance driving transmucosal drug delivery in pain management 426 10.8.2 HORMONE THERAPY 427 10.8.2.1 Need for controlled hormone delivery and long-term therapy driving transmucosal drug delivery in hormonal therapy 427 10.8.3 INFECTIOUS DISEASES 429 10.8.3.1 Targeted local therapy and improved patient compliance driving transmucosal drug delivery in infectious diseases 429 10.8.4 OTHER TRANSMUCOSAL DRUG DELIVERY APPLICATIONS 430 10.9 IMPLANTABLE DRUG DELIVERY 431 10.9.1 HORMONAL THERAPY/CONTRACEPTION 433 10.9.1.1 Long-acting reversible contraceptives and sustained hormone delivery driving market 433   10.9.2 CANCER 434 10.9.2.1 Targeted therapy and sustained drug release driving implantable drug delivery in cancer 434 10.9.3 OTHER IMPLANTABLE DRUG DELIVERY APPLICATIONS 435 10.10 OTIC DRUG DELIVERY 437 10.10.1 EAR INFECTIONS 438 10.10.1.1 High incidence of otitis and pediatric burden driving otic drug delivery in ear infections 438 10.10.2 CERUMEN REMOVAL 440 10.10.2.1 Growing demand for ear hygiene and non-invasive treatments driving otic drug delivery in cerumen removal 440 10.10.3 OTHER OTIC DRUG DELIVERY APPLICATIONS 441 11 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 443 11.1 INTRODUCTION 444 11.2 FORMULATIONS, BY FACILITY OF USE 444 11.2.1 HOSPITALS 446 11.2.1.1 Increased hospital demand for complex drug delivery boosts market uptake 446 11.2.2 HOME CARE SETTINGS 448 11.2.2.1 Rising preference for self-administration of medicine to drive market 448 11.2.3 AMBULATORY SURGERY CENTERS/CLINICS 450 11.2.3.1 Shift toward cost-effective outpatient care driving adoption of drug delivery systems 450 11.2.4 DIAGNOSTIC CENTERS 452 11.2.4.1 Rising prevalence of chronic diseases to support market growth 452 11.2.5 LONG-TERM CARE SETTINGS 453 11.2.5.1 Growing elderly population and chronic disease burden to drive market 453 11.2.6 OTHER FACILITIES OF USE 455 11.3 DEVICES, BY FACILITY OF USE 456 11.3.1 PHARMACEUTICAL COMPANIES 458 11.3.1.1 Increasing focus on advanced drug delivery systems driving market growth 458 11.3.2 BIOTECHNOLOGY COMPANIES 460 11.3.2.1 Enabling complex biologics delivery and decentralized care 460 11.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) 461 11.3.3.1 Fueling innovation through cost-effective and scalable manufacturing solutions 461 12 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION 464 12.1 INTRODUCTION 465 12.2 NORTH AMERICA 466 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 467 12.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 469 12.2.3 US 485 12.2.3.1 US to dominate North American pharmaceutical drug delivery market 485 12.2.4 CANADA 501 12.2.4.1 Government support for research and the prevalence of chronic diseases to drive the market in Canada 501 12.3 EUROPE 518 12.3.1 EUROPE: MACROECONOMIC OUTLOOK 519 12.3.2 EUROPE: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 519 12.3.3 GERMANY 535 12.3.3.1 Growing focus of pharmaceutical companies on the development of various drug delivery products to drive market 535 12.3.4 UK 552 12.3.4.1 NHS support and growing access to cost-effective pen needles to drive the market 552 12.3.5 FRANCE 568 12.3.5.1 Presence of leading pharmaceutical companies, along with the increasing prevalence of chronic diseases, to drive market growth in France 568 12.3.6 ITALY 584 12.3.6.1 Increasing focus on clinical research and growing popularity of branded drugs to drive demand for pharmaceutical drug manufacturing 584 12.3.7 DENMARK 600 12.3.7.1 Strong R&D ecosystem, biologics innovation, and export-driven pharmaceutical manufacturing to drive demand for pharmaceutical drug delivery 600 12.3.8 SWEDEN 616 12.3.8.1 Strong life sciences ecosystem, biologics innovation, and government-backed healthcare system to drive demand for pharmaceutical drug delivery 616 12.3.9 SPAIN 631 12.3.9.1 Increase in biologics production to support market growth 631 12.3.10 NETHERLANDS 648 12.3.10.1 Enhancing patient care through innovation and collaboration to drive market growth 648 12.3.11 REST OF EUROPE 664 12.4 ASIA PACIFIC 680 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 680 12.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 681 12.4.3 CHINA 698 12.4.3.1 A high diabetic population and rising prevalence of chronic diseases contribute to China’s large demand 698   12.4.4 JAPAN 714 12.4.4.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan 714 12.4.5 INDIA 731 12.4.5.1 Growing generic demand and rising government initiatives to drive market 731 12.4.6 AUSTRALIA 747 12.4.6.1 Rising investment and a favorable tax environment to support growth 747 12.4.7 SOUTH KOREA 763 12.4.7.1 Strong government support and investments in healthcare & biopharmaceuticals to propel growth 763 12.4.8 NEW ZEALAND 779 12.4.8.1 Strong public healthcare system, rising biologics adoption, and focus on advanced therapies to drive demand 779 12.4.9 THAILAND 795 12.4.9.1 Regulatory reforms and healthcare initiatives to fuel market growth 795 12.4.10 REST OF ASIA PACIFIC 812 12.5 LATIN AMERICA 828 12.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM 828 12.5.2 LATIN AMERICA: MACROECONOMIC OUTLOOK 829 12.5.3 LATIN AMERICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 829 12.5.4 BRAZIL 846 12.5.4.1 Brazil attracting multinational pharmaceutical companies 846 12.5.5 MEXICO 862 12.5.5.1 Growth and diversification in Mexico's pharmaceutical exports 862 12.5.6 ARGENTINA 878 12.5.6.1 Expanding domestic pharmaceutical production, increasing chronic disease burden, and growing biologics adoption to drive demand 878 12.5.7 REST OF LATIN AMERICA 894 12.6 MIDDLE EAST & AFRICA 910 12.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 910 12.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024–2031 911 12.6.3 GCC COUNTRIES 927 12.6.3.1 Kingdom of Saudi Arabia (KSA) 943 12.6.3.1.1 Healthcare reforms and global partnerships fuel pharmaceutical market growth 943 12.6.3.2 United Arab Emirates (UAE) 959 12.6.3.2.1 Government supports and growing local manufacturing to drive market growth 959 12.6.3.3 Rest of GCC Countries 975 12.6.4 REST OF MIDDLE EAST & AFRICA 991 13 COMPETITIVE LANDSCAPE 1008 13.1 OVERVIEW 1008 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 1008 13.3 REVENUE ANALYSIS, 2023–2025 1010 13.3.1 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS 1010 13.3.2 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS 1011 13.4 MARKET SHARE ANALYSIS, 2025 1011 13.4.1 GLOBAL INJECTABLE DRUG DELIVERY MANUFACTURERS 1011 13.4.1.1 Global Injectable Drug Delivery Device Manufacturers 1011 13.4.1.2 GLOBAL INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS 1014 13.4.1.2.1 US Injectable Drug Delivery Formulation Manufacturers 1016 13.4.1.3 Europe Injectable drug delivery formulation manufacturers 1017 13.4.2 GLOBAL ORAL DRUG DELIVERY MANUFACTURERS 1018 13.4.2.1 US oral drug delivery formulation manufacturers 1019 13.4.2.2 Europe oral drug delivery manufacturers 1020 13.4.3 GLOBAL TOPICAL DRUG DELIVERY MANUFACTURERS 1021 13.4.3.1 US Topical Drug Delivery Formulation Manufacturers 1022 13.4.3.2 Europe Topical Drug Delivery Manufacturers 1023 13.5 BRAND/PRODUCT COMPARISON 1025 13.6 R&D EXPENDITURE OF KEY PLAYERS 1026 13.7 COMPANY VALUATION AND FINANCIAL METRICS 1026 13.7.1 COMPANY VALUATION 1026 13.7.2 FINANCIAL METRICS 1027 13.8 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1027 13.8.1 STARS 1027 13.8.2 EMERGING LEADERS 1028 13.8.3 PERVASIVE PLAYERS 1028 13.8.4 PARTICIPANTS 1028 13.8.5 COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1029 13.8.5.1 Company footprint 1029 13.8.5.2 Region footprint 1030 13.8.5.3 Product type footprint 1030 13.8.5.4 Usability footprint 1031 13.9 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1031 13.9.1 STARS 1031 13.9.2 EMERGING LEADERS 1032 13.9.3 PERVASIVE PLAYERS 1032 13.9.4 PARTICIPANTS 1032 13.9.5 COMPANY FOOTPRINT: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1033 13.9.5.1 Company footprint 1033 13.9.5.2 Region footprint 1034 13.9.5.3 Route of administration footprint 1035 13.9.5.4 Therapeutic application footprint 1036 13.10 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025 1037 13.10.1 PROGRESSIVE COMPANIES 1037 13.10.2 DYNAMIC COMPANIES 1037 13.10.3 STARTING BLOCKS 1037 13.10.4 RESPONSIVE COMPANIES 1037 13.10.5 COMPETITIVE BENCHMARKING: PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES, 2025 1039 13.10.5.1 Detailed list of key startups/SMEs 1039 13.10.5.2 Competitive benchmarking of startups/SMEs 1039 13.11 COMPETITIVE SCENARIO 1040 13.11.1 PRODUCT APPROVALS AND LAUNCHES 1040 13.11.2 DEALS 1041 13.11.3 EXPANSIONS 1042 13.11.4 OTHER DEVELOPMENTS 1043 14 COMPANY PROFILES 1044 14.1 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS 1044 14.1.1 JOHNSON & JOHNSON 1044 14.1.1.1 Business overview 1044 14.1.1.2 Products offered 1045 14.1.1.3 Recent developments 1047 14.1.1.3.1 Product approvals 1047 14.1.1.3.2 Deals 1054 14.1.1.3.3 Expansions 1056 14.1.1.3.4 Other developments 1056 14.1.1.4 MnM view 1057 14.1.1.4.1 Right to win 1057 14.1.1.4.2 Strategic choices 1057 14.1.1.4.3 Weaknesses and competitive threats 1057 14.1.2 NOVARTIS AG 1058 14.1.2.1 Business overview 1058 14.1.2.2 Products offered 1059 14.1.2.3 Recent developments 1062 14.1.2.3.1 Product launches & approvals 1062 14.1.2.3.2 Deals 1064 14.1.2.3.3 Expansions 1066 14.1.2.3.4 Other developments 1067 14.1.2.4 MnM view 1067 14.1.2.4.1 Right to win 1067 14.1.2.4.2 Strategic choices 1068 14.1.2.4.3 Weaknesses and competitive threats 1068 14.1.3 F. HOFFMANN-LA ROCHE LTD 1069 14.1.3.1 Business overview 1069 14.1.3.2 Products offered 1070 14.1.3.3 Recent developments 1072 14.1.3.3.1 Product launches & approvals 1072 14.1.3.3.2 Deals 1077 14.1.3.3.3 Expansions 1078 14.1.3.3.4 Other developments 1079 14.1.3.4 MnM view 1079 14.1.3.4.1 Right to win 1079 14.1.3.4.2 Strategic choices 1079 14.1.3.4.3 Weaknesses and competitive threats 1079 14.1.4 PFIZER INC. 1080 14.1.4.1 Business overview 1080 14.1.4.2 Products offered 1081 14.1.4.3 Recent developments 1087 14.1.4.3.1 Product launches & approvals 1087 14.1.4.3.2 Deals 1090 14.1.4.4 MnM view 1092 14.1.4.4.1 Right to win 1092 14.1.4.4.2 Strategic choices 1092 14.1.4.4.3 Weaknesses and competitive threats 1092 14.1.5 ELI LILLY AND COMPANY 1093 14.1.5.1 Business overview 1093 14.1.5.2 Products offered 1094 14.1.5.3 Recent developments 1095 14.1.5.3.1 Product launches & approvals 1095 14.1.5.3.2 Deals 1098 14.1.5.3.3 Expansions 1100 14.1.6 GSK PLC. 1103 14.1.6.1 Business overview 1103 14.1.6.2 Products offered 1104 14.1.6.3 Recent developments 1109 14.1.6.3.1 Product launches & approvals 1109 14.1.6.3.2 Deals 1112 14.1.6.3.3 Other developments 1115   14.1.7 ABBVIE INC. 1116 14.1.7.1 Business overview 1116 14.1.7.2 Products offered 1117 14.1.7.3 Recent developments 1121 14.1.7.3.1 Product approvals 1121 14.1.7.3.2 Deals 1123 14.1.7.3.3 Expansions 1126 14.1.7.3.4 Other developments 1127 14.1.8 MERCK & CO., INC. 1128 14.1.8.1 Business overview 1128 14.1.8.2 Products offered 1129 14.1.8.3 Recent developments 1132 14.1.8.3.1 Product launches & approvals 1132 14.1.8.3.2 Deals 1137 14.1.8.3.3 Expansions 1140 14.1.8.3.4 Other developments 1140 14.1.9 BAUSCH HEALTH COMPANIES INC. 1141 14.1.9.1 Business overview 1141 14.1.9.2 Products offered 1142 14.1.9.3 Recent developments 1145 14.1.9.3.1 Product launches & approvals 1145 14.1.9.3.2 Deals 1146 14.1.10 BAYER AG 1147 14.1.10.1 Business overview 1147 14.1.10.2 Products offered 1148 14.1.10.3 Recent developments 1150 14.1.10.3.1 Product launches & approvals 1150 14.1.10.3.2 Deals 1155 14.1.10.3.3 Expansions 1157 14.1.10.3.4 Other developments 1158 14.1.11 AMGEN INC. 1159 14.1.11.1 Business overview 1159 14.1.11.2 Products offered 1160 14.1.11.3 Recent developments 1161 14.1.11.3.1 Product launches & approvals 1161 14.1.11.3.2 Deals 1163 14.1.11.3.3 Expansions 1164 14.1.12 ASTRAZENECA 1166 14.1.12.1 Business overview 1166 14.1.12.2 Products offered 1167 14.1.12.3 Recent developments 1170 14.1.12.3.1 Product launches & approvals 1170 14.1.12.3.2 Deals 1177 14.1.12.3.3 Expansions 1178 14.1.12.3.4 Other developments 1179 14.1.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 1180 14.1.13.1 Business overview 1180 14.1.13.2 Products offered 1181 14.1.13.3 Recent developments 1182 14.1.13.3.1 Product launches & approvals 1182 14.1.13.3.2 Deals 1183 14.1.13.4 Recent developments 1186 14.1.13.4.1 Expansions 1186 14.2 OTHER PLAYERS 1187 14.2.1 SANOFI 1187 14.2.2 NOVO NORDISK A/S 1189 14.2.3 GLENMARK PHARMACEUTICALS LTD. 1191 14.2.4 VIATRIS INC 1195 14.2.5 BRISTOL-MYERS SQUIBB COMPANY 1197 14.2.6 RUSAN PHARMA LTD. 1199 14.2.7 CMP PHARMA, INC. 1200 14.2.8 XERIS PHARMACEUTICALS, INC. 1201 14.2.9 ADHEXPHARMA 1202 14.3 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS 1203 14.3.1 BD 1203 14.3.1.1 Business overview 1203 14.3.1.2 Products offered 1204 14.3.1.3 Recent developments 1207 14.3.1.3.1 Deals 1207 14.3.1.3.2 Expansions 1207 14.3.1.3.3 Other developments 1208 14.3.1.4 MnM view 1208 14.3.1.4.1 Right to win 1208 14.3.1.4.2 Strategic choices 1208 14.3.1.4.3 Weaknesses and competitive threats 1208 14.3.2 CARDINAL HEALTH 1209 14.3.2.1 Business overview 1209 14.3.2.2 Products offered 1210 14.3.2.3 Recent developments 1211 14.3.2.3.1 Expansions 1211 14.3.2.4 MnM view 1211 14.3.2.4.1 Right to win 1211 14.3.2.4.2 Strategic choices 1212 14.3.2.4.3 Weaknesses and competitive threats 1212 14.3.3 B. BRAUN SE 1213 14.3.3.1 Business overview 1213 14.3.3.2 Products offered 1214 14.3.4 TERUMO CORPORATION 1216 14.3.4.1 Business overview 1216 14.3.4.2 Products offered 1217 14.3.4.3 Recent developments 1218 14.3.4.3.1 Product launches & approvals 1218 14.3.4.3.2 Expansions 1219 14.3.5 NIPRO 1220 14.3.5.1 Business overview 1220 14.3.5.2 Products offered 1221 14.3.5.3 Recent developments 1222 14.3.5.3.1 Expansions 1222 14.3.6 STEVANATO GROUP 1223 14.3.6.1 Business overview 1223 14.3.6.2 Products offered 1224 14.3.6.3 Recent developments 1225 14.3.6.3.1 Product launches & approvals 1225 14.3.6.3.2 Deals 1225 14.3.6.3.3 Expansions 1226 14.3.6.3.4 Other developments 1227 14.3.7 GERRESHEIMER AG 1228 14.3.7.1 Business overview 1228 14.3.7.2 Products offered 1229 14.3.7.3 Recent developments 1230 14.3.7.3.1 Product launches & approvals 1230 14.3.7.3.2 Deals 1231 14.3.7.3.3 Expansions 1232 14.3.8 WEST PHARMACEUTICAL SERVICES, INC. 1233 14.3.8.1 Business overview 1233 14.3.8.2 Products offered 1234 14.3.8.3 Recent developments 1235 14.3.8.3.1 Product launches & approvals 1235 14.3.8.3.2 Deals 1235 14.3.8.3.3 Expansions 1236 14.3.9 YPSOMED 1237 14.3.9.1 Business overview 1237 14.3.9.2 Products offered 1238   14.3.9.3 Recent developments 1239 14.3.9.3.1 Product launches 1239 14.3.9.3.2 Deals 1239 14.3.9.3.3 Expansions 1241 14.3.10 SHL MEDICAL AG 1242 14.3.10.1 Business overview 1242 14.3.10.2 Products offered 1242 14.3.10.3 Recent developments 1243 14.3.10.3.1 Product launches 1243 14.3.10.3.2 Deals 1244 14.3.10.3.3 Expansions 1245 15 RESEARCH METHODOLOGY 1246 15.1 RESEARCH DATA 1246 15.1.1 SECONDARY DATA 1247 15.1.1.1 Key secondary sources 1248 15.1.2 PRIMARY DATA 1248 15.1.2.1 Primary sources 1249 15.1.2.2 Key data from primary sources 1250 15.1.2.3 Key industry insights 1251 15.1.2.4 Breakdown of primaries 1251 15.2 MARKET SIZE ESTIMATION 1252 15.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH 1254 15.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 1255 15.2.3 APPROACH 3: TOP-DOWN APPROACH 1255 15.2.4 APPROACH 4: BOTTOM-UP APPROACH 1256 15.2.5 APPROACH 4: PRIMARY INTERVIEWS 1256 15.2.6 APPROACH 5: DEMAND-SIDE APPROACH 1256 15.2.7 APPROACH 6: VOLUME DATA ANALYSIS 1257 15.3 DATA TRIANGULATION AND MARKET BREAKDOWN 1260 15.4 MARKET SHARE ASSESSMENT 1262 15.5 RESEARCH ASSUMPTIONS 1262 15.5.1 STUDY ASSUMPTIONS 1262 15.5.2 GROWTH RATE ASSUMPTIONS 1262 15.6 RISK ASSESSMENT 1263 15.6.1 RESEARCH LIMITATIONS 1263   16 APPENDIX 1264 16.1 DISCUSSION GUIDE 1264 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 1279 16.3 CUSTOMIZATION OPTIONS 1281 16.3.1 PRODUCT ANALYSIS 1281 16.3.2 COMPANY INFORMATION 1281 16.3.3 GEOGRAPHIC ANALYSIS 1281 16.3.4 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT 1281 16.3.5 BY ROUTE OF ADMINISTRATION MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 1281 16.3.6 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS 1281 16.4 RELATED REPORTS 1282 16.5 AUTHOR DETAILS 1283
圖表清單 List of Tables & Figures
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 108 TABLE 2 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE, 2024 121 TABLE 3 KEY DEVELOPMENTS IN PRE-FILLED SYRINGES AND PEN INJECTORS, 2024–2025 122 TABLE 4 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS (20–79 YEARS), 2021 VS. 2045 123 TABLE 5 KEY BIOSIMILARS/GENERICS WITH INJECTABLE DRUG DELIVERY DEVICES 125 TABLE 6 PHARMACEUTICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 135 TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (IN USD BILLION) 138 TABLE 8 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025 144 TABLE 9 AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025 145 TABLE 10 AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS, BY KEY PLAYER, 2023–2025 145 TABLE 11 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025 146 TABLE 12 AVERAGE SELLING PRICE TREND OF ORAL DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025 147 TABLE 13 AVERAGE SELLING PRICE TREND OF TOPICAL DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025 147 TABLE 14 AVERAGE SELLING PRICE TREND OF PULMONARY DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025 147 TABLE 15 AVERAGE SELLING PRICE TREND OF OCULAR DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025 148 TABLE 16 AVERAGE SELLING PRICE TREND OF NASAL DRUG DELIVERY PRODUCTS, BY REGION, 2023−2025 148 TABLE 17 IMPORT DATA FOR HS CODE 9021, BY COUNTRY, 2021–2025 (USD THOUSAND) 149 TABLE 18 EXPORT DATA FOR HS CODE 3004, BY COUNTRY, 2021–2025 (USD THOUSAND) 150 TABLE 19 IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 150 TABLE 20 EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 151 TABLE 21 PHARMACEUTICAL DRUG DELIVERY MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 151 TABLE 22 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE 155 TABLE 23 CASE STUDY 1: MEDTRONIC – INSULIN PUMP DRUG DELIVERY SYSTEM 166 TABLE 24 CASE STUDY 2: YPSOMED – SMARTPILOT CONNECTED DRUG DELIVERY 167 TABLE 25 CASE STUDY 3: ENABLE INJECTIONS – ENFUSE CLINICAL PERFORMANCE 168 TABLE 26 US-ADJUSTED RECIPROCAL TARIFF RATES 169 TABLE 27 KEY PRODUCT-RELATED TARIFFS EFFECTIVE PHARMACEUTICAL DRUG DELIVERY PRODUCTS 170 TABLE 28 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA 171 TABLE 29 ASIA PACIFIC: IMPACT OF US TARIFF ON CHINA, JAPAN, AND INDIA 171 TABLE 30 EUROPE: IMPACT OF US TARIFF ON GERMANY AND UK 172 TABLE 31 LATIN AMERICA: IMPACT OF US TARIFF ON MEXICO 172 TABLE 32 PHARMACEUTICAL DRUG DELIVERY MARKET: MAJOR PATENTS 182 TABLE 33 KEY COMPANIES IMPLEMENTING AI IN PHARMACEUTICAL DRUG DELIVERY MARKET 186 TABLE 34 REGULATORY SCENARIO BY COUNTRY 187 TABLE 35 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 190 TABLE 36 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 190 TABLE 37 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 191 TABLE 38 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 192 TABLE 39 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 192 TABLE 40 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 192 TABLE 41 PHARMACEUTICAL DRUG DELIVERY MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (DEVICES) 197 TABLE 42 PHARMACEUTICAL DRUG DELIVERY MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (FORMULATIONS) 198 TABLE 43 KEY BUYING CRITERIA FOR TOP THREE END USERS 199 TABLE 44 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 205 TABLE 45 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 206 TABLE 46 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 206 TABLE 47 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY DEVICES 207 TABLE 48 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2024–2031 (USD BILLION) 209 TABLE 49 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2 024–2031 (USD BILLION) 210 TABLE 50 KEY PLAYERS PROVIDING CONVENTIONAL INJECTION DEVICES 211 TABLE 51 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 213 TABLE 52 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 214 TABLE 53 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2024–2031 (USD BILLION) 215 TABLE 54 KEY PLAYERS PROVIDING CONVENTIONAL GLASS INJECTION DEVICES 216 TABLE 55 CONVENTIONAL GLASS INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 216 TABLE 56 KEY PLAYERS PROVIDING CONVENTIONAL PLASTIC INJECTION DEVICES 217 TABLE 57 CONVENTIONAL PLASTIC INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 218 TABLE 58 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2024–2031 (USD BILLION) 219 TABLE 59 KEY PLAYERS PROVIDING REUSABLE INJECTION DEVICES 220 TABLE 60 CONVENTIONAL REUSABLE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 220 TABLE 61 KEY PLAYERS PROVIDING DISPOSABLE INJECTION DEVICES 221 TABLE 62 CONVENTIONAL DISPOSABLE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 222 TABLE 63 CONVENTIONAL INJECTION DEVICES MARKET, BY TYPE, 2024–2031 (USD BILLION) 223 TABLE 64 KEY PLAYERS PROVIDING FILLABLE SYRINGES 223 TABLE 65 FILLABLE SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 224 TABLE 66 KEY PLAYERS PROVIDING PREFILLED SYRINGES 225 TABLE 67 PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 225 TABLE 68 KEY PLAYERS PROVIDING SELF-INJECTION DEVICES 226 TABLE 69 SELF-INJECTION DEVICES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 228 TABLE 70 SELF-INJECTION DEVICES MARKET, BY PRODUCT TYPE, 2024–2031 (USD BILLION) 228 TABLE 71 SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 228 TABLE 72 KEY PLAYERS PROVIDING NEEDLE-FREE INJECTORS 230 TABLE 73 NEEDLE-FREE INJECTION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 230 TABLE 74 KEY PLAYERS PROVIDING AUTOINJECTORS 231 TABLE 75 AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 232 TABLE 76 KEY PLAYERS PROVIDING PEN INJECTORS 233 TABLE 77 PEN INJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 234 TABLE 78 KEY PLAYERS PROVIDING WEARABLE INJECTORS 235 TABLE 79 WEARABLE INJECTORS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 235 TABLE 80 KEY PLAYERS PROVIDING OTHER INJECTABLE DEVICES 236 TABLE 81 OTHER INJECTABLE DRUG DEVICES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 237 TABLE 82 KEY PLAYERS PROVIDING FORMULATIONS 238 TABLE 83 FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 239 TABLE 84 FORMULATIONS MARKET, BY TYPE, 2024–2031 (USD BILLION) 240 TABLE 85 KEY PLAYERS PROVIDING CONVENTIONAL DRUG DELIVERY FORMULATIONS 241 TABLE 86 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 242 TABLE 87 KEY PLAYERS PROVIDING NOVEL DRUG DELIVERY FORMULATIONS 243 TABLE 88 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 244 TABLE 89 KEY PLAYERS PROVIDING LONG-ACTING FORMULATIONS 245 TABLE 90 LONG-ACTING FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 245 TABLE 91 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 247 TABLE 92 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY COUNTRY, 2024–2031 (USD BILLION) 248 TABLE 93 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY COUNTRY, 2024–2031 (USD BILLION) 249 TABLE 94 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY COUNTRY, 2024–2031 (USD BILLION) 250 TABLE 95 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY COUNTRY, BY COUNTRY 2024–2031 (USD BILLION) 251 TABLE 96 ORAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 253 TABLE 97 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 253 TABLE 98 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY TYPE, 2024–2031 (USD BILLION) 255 TABLE 99 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2024–2031 (USD BILLION) 255 TABLE 100 TABLETS MARKET, BY REGION, 2024–2031 (USD BILLION) 257 TABLE 101 CAPSULES MARKET, BY REGION, 2024–2031 (USD BILLION) 258 TABLE 102 POWDERS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 259 TABLE 103 GRANULES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 261 TABLE 104 LOZENGES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 262 TABLE 105 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY TYPE, 2024–2031 (USD BILLION) 264 TABLE 106 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY, 2024–2031 (USD MILLION) 264 TABLE 107 ORAL SYRUPS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 265 TABLE 108 ORAL SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 267 TABLE 109 ORAL EMULSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 268 TABLE 110 ORAL SUSPENSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 269 TABLE 111 ORAL ELIXIRS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 271 TABLE 112 ORAL DRUG DELIVERY MARKET FOR SEMI-SOLID DRUGS, BY TYPE, 2024–2031 (USD BILLION) 272 TABLE 113 ORAL DRUG DELIVERY MARKET FOR SEMI-SOLID DRUGS, BY COUNTRY, 2024–2031 (USD BILLION) 272 TABLE 114 ORAL GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 273 TABLE 115 ORAL PASTES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 275 TABLE 116 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 276 TABLE 117 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 118 KEY SEMI-SOLID FORMULATIONS CURRENTLY AVAILABLE 279 TABLE 119 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION) 280 TABLE 120 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 280 TABLE 121 KEY OINTMENTS CURRENTLY OFFERED 282 TABLE 122 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 282 TABLE 123 KEY CREAMS CURRENTLY AVAILABLE 284 TABLE 124 TOPICAL CREAMS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 284 TABLE 125 KEY PLAYERS PROVIDING LOTIONS 285 TABLE 126 TOPICAL LOTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 286 TABLE 127 KEY PLAYERS PROVIDING GELS 287 TABLE 128 TOPICAL GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 288 TABLE 129 KEY PASTES CURRENTLY AVAILABLE 289 TABLE 130 TOPICAL PASTES MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 289 TABLE 131 KEY LIQUID FORMULATIONS CURRENTLY AVAILABLE 291 TABLE 132 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION) 291 TABLE 133 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 291 TABLE 134 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 293 TABLE 135 TOPICAL EMULSIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 294 TABLE 136 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 296 TABLE 137 KEY SOLID FORMULATIONS CURRENTLY AVAILABLE 297 TABLE 138 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION) 298 TABLE 139 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 298 TABLE 140 KEY PLAYERS PROVIDING POWDERS 299 TABLE 141 TOPICAL POWDERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 299 TABLE 142 KEY PLAYERS PROVIDING SUPPOSITORIES 301 TABLE 143 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 301 TABLE 144 KEY PLAYERS PROVIDING FILMS 302 TABLE 145 TOPICAL FILMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 303 TABLE 146 KEY TRANSDERMAL PRODUCTS CURRENTLY AVAILABLE 304 TABLE 147 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2024–2031 (USD BILLION) 305 TABLE 148 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2024–2031 (USD BILLION) 305 TABLE 149 KEY PLAYERS PROVIDING TRANSDERMAL PATCHES 307 TABLE 150 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 307 TABLE 151 KEY PLAYERS PROVIDING TRANSDERMAL GELS 308 TABLE 152 TRANSDERMAL GELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 308 TABLE 153 KEY PLAYERS PROVIDING TRANSDERMAL SPRAYS 310 TABLE 154 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 310 TABLE 155 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 311 TABLE 156 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 312 TABLE 157 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION) 313 TABLE 158 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 313 TABLE 159 COMMERCIALLY AVAILABLE EYE DROPS 315 TABLE 160 EYE DROPS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 315 TABLE 161 LIQUID SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 316 TABLE 162 OCULAR DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION) 317 TABLE 163 OCULAR DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 318 TABLE 164 OCULAR GELS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 319 TABLE 165 EYE OINTMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 320 TABLE 166 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2024–2031 (USD BILLION) 322 TABLE 167 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY, 2024–2031 (USD BILLION) 322 TABLE 168 DRUG-COATED CONTACT LENSES MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 323 TABLE 169 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 324 TABLE 170 OCULAR INSERTS MARKET, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 325 TABLE 171 OCULAR INSERTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 326 TABLE 172 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 327 TABLE 173 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 328 TABLE 174 PULMONARY DRUG DELIVERY DEVICE MARKET, BY TYPE, 2024–2031 (USD BILLION) 329 TABLE 175 PULMONARY DRUG DELIVERY DEVICE MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 329 TABLE 176 PULMONARY DRUG DELIVERY MARKET FOR METERED DOSE INHALERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 331 TABLE 177 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS, BY COUNTRY, 2024–2031 (USD BILLION) 331 TABLE 178 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 333 TABLE 179 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY COUNTRY, 2024–2031 (USD BILLION) 333 TABLE 180 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY REGION, 2024–2031 (TEN THOUSAND UNITS) 335 TABLE 181 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2024–2031 (USD BILLION) 335 TABLE 182 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY, 2024–2031 (USD BILLION) 336 TABLE 183 JET NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 337 TABLE 184 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 338 TABLE 185 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 339 TABLE 186 PULMONARY DRUG DELIVERY FORMULATION MARKET, BY TYPE, 2024–2031 (USD BILLION) 341 TABLE 187 PULMONARY DRUG DELIVERY FORMULATION MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 341 TABLE 188 PULMONARY DRUG DELIVERY MARKET FOR SUSPENSION AEROSOL, BY COUNTRY, 2024–2031 (USD BILLION) 342 TABLE 189 PULMONARY DRUG DELIVERY MARKET FOR SOLUTION AEROSOL, BY COUNTRY, 2024–2031 (USD BILLION) 343 TABLE 190 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 345 TABLE 191 NASAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 346 TABLE 192 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 347 TABLE 193 NASAL DROPS & LIQUIDS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 348 TABLE 194 NASAL SPRAYS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 350 TABLE 195 NASAL POWDERS MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 351 TABLE 196 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 353 TABLE 197 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 353 TABLE 198 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2024–2031 (USD BILLION) 354 TABLE 199 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 355 TABLE 200 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 356 TABLE 201 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 358 TABLE 202 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, BY TYPE, 2024–2031 (USD BILLION) 359 TABLE 203 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 359 TABLE 204 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 361 TABLE 205 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 362 TABLE 206 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 364 TABLE 207 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 364 TABLE 208 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 365 TABLE 209 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 367 TABLE 210 OTIC DRUG DELIVERY MARKET, BY TYPE, 2024–2031 (USD BILLION) 368 TABLE 211 OTIC DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 368 TABLE 212 OTIC DRUG DELIVERY MARKET FOR EAR DROPS, BY COUNTRY, 2024–2031 (USD MILLION) 370 TABLE 213 OTIC DRUG DELIVERY MARKET BY OTIC SPRAYS, BY COUNTRY, 2024–2031 (USD BILLION) 372 TABLE 214 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS 375 TABLE 215 INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 375 TABLE 216 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 376 TABLE 217 INJECTABLE DRUG DELIVERY MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION) 377 TABLE 218 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD BILLION 379 TABLE 219 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNOLOGICAL & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 380 TABLE 220 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 382 TABLE 221 INJECTABLE DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 384 TABLE 222 ORAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 386 TABLE 223 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 386 TABLE 224 ORAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 387 TABLE 225 ORAL DRUG DELIVERY MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION) 389 TABLE 226 ORAL DRUG DELIVERY MARKET FOR CNS DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION) 390 TABLE 227 ORAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 392 TABLE 228 ORAL DRUG DELIVERY MARKET FOR ONCOLOGY (ORAL THERAPIES), BY COUNTRY, 2024–2031 (USD BILLION) 394 TABLE 229 ORAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 396 TABLE 230 TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 398 TABLE 231 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 398 TABLE 232 TOPICAL DRUG DELIVERY MARKET FOR DERMATOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION) 400 TABLE 233 TOPICAL DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2024–2031 (USD BILLION) 401 TABLE 234 TOPICAL DRUG DELIVERY MARKET FOR WOUND CARE, BY COUNTRY, 2024–2031 (USD BILLION) 402 TABLE 235 OCULAR DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION 404 TABLE 236 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 404 TABLE 237 OCULAR DRUG DELIVERY MARKET FOR RETINAL DISORDERS, BY COUNTRY, 2024–2031 (USD BILLION) 406 TABLE 238 OCULAR DRUG DELIVERY MARKET FOR GLAUCOMA, BY COUNTRY, 2024–2031 (USD BILLION) 407 TABLE 239 OCULAR DRUG DELIVERY MARKET FOR EYE INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 409 TABLE 240 OCULAR DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 410 TABLE 241 PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION 412 TABLE 242 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 412 TABLE 243 PULMONARY DRUG DELIVERY MARKET FOR ASTHMA, BY COUNTRY, 2024–2031 (USD BILLION) 414 TABLE 244 PULMONARY DRUG DELIVERY MARKET FOR COPD, BY COUNTRY, 2024–2031 (USD BILLION) 415 TABLE 245 PULMONARY DRUG DELIVERY MARKET FOR PULMONARY INFECTIONS, BY COUNTRY, 2024–2031 (USD BILLION) 416 TABLE 246 PULMONARY DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 418 TABLE 247 NASAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 419 TABLE 248 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 419 TABLE 249 NASAL DRUG DELIVERY MARKET FOR ALLERGIC RHINITIS, BY COUNTRY, 2024–2031 (USD BILLION) 421 TABLE 250 NASAL DRUG DELIVERY MARKET FOR SINUSITIS, BY COUNTRY, 2024–2031 (USD BILLION) 422 TABLE 251 NASAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 423 TABLE 252 TRANSMUCOSAL DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 425 TABLE 253 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 425 TABLE 254 TRANSMUCOSAL DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2024–2031 (USD BILLION) 426 TABLE 255 TRANSMUCOSAL DRUG DELIVERY MARKET FOR HORMONE THERAPY, BY COUNTRY, 2024–2031 (USD BILLION) 428 TABLE 256 TRANSMUCOSAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD BILLION) 429 TABLE 257 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 430 TABLE 258 IMPLANTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 432 TABLE 259 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 432 TABLE 260 IMPLANTABLE DRUG DELIVERY MARKET FOR HORMONAL THERAPY/CONTRACEPTION, BY COUNTRY, 2024–2031 (USD BILLION) 433 TABLE 261 IMPLANTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD BILLION) 435 TABLE 262 IMPLANTABLE DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 436 TABLE 263 OTIC DRUG DELIVERY MARKET, BY APPLICATION, 2024–2031 (USD BILLION) 437 TABLE 264 OTIC DRUG DELIVERY MARKET, BY, APPLICATION, BY COUNTRY, 2024–2031 (USD BILLION) 437 TABLE 265 OTIC DRUG DELIVERY MARKET FOR EAR INFECTIONS, BY COUNTRY, 2024–2031 (USD BILLION) 439 TABLE 266 OTIC DRUG DELIVERY MARKET FOR CERUMEN REMOVAL, BY COUNTRY, 2024–2031 (USD BILLION) 440 TABLE 267 OTIC DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD BILLION) 441 TABLE 268 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION) 444 TABLE 269 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION) 445 TABLE 270 FACILITY OF USE: PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 445 TABLE 271 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 447 TABLE 272 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 449 TABLE 273 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 451 TABLE 274 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 452 TABLE 275 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR LONG-TERM CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 454 TABLE 276 PHARMACEUTICAL DRUG DELIVERY FORMULATIONS MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2024–2031 (USD MILLION) 455 TABLE 277 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET, BY FACILITY OF USE, 2024–2031 (USD MILLION) 457 TABLE 278 FACILITY OF USE: PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 457 TABLE 279 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 459 TABLE 280 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 460 TABLE 281 PHARMACEUTICAL DRUG DELIVERY DEVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 462 TABLE 282 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2024–2031 (USD BILLION) 466 TABLE 283 NORTH AMERICA: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS) 469 TABLE 284 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024-2031 (USD BILLION) 469 TABLE 285 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 470 TABLE 286 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 470 TABLE 287 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 471 TABLE 288 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY MATERIAL, 2024-2031 (USD BILLION) 471 TABLE 289 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY USABILITY, 2024-2031 (USD BILLION) 471 TABLE 290 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 472 TABLE 291 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 472 TABLE 292 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 472 TABLE 293 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 473 TABLE 294 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 473 TABLE 295 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 473 TABLE 296 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 474 TABLE 297 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 474 TABLE 298 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 474 TABLE 299 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 475 TABLE 300 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 475 TABLE 301 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 475 TABLE 302 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 476 TABLE 303 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 476 TABLE 304 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 476 TABLE 305 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 477 TABLE 306 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 477 TABLE 307 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 477 TABLE 308 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 478 TABLE 309 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 478 TABLE 310 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 478 TABLE 311 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 479 TABLE 312 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 479 TABLE 313 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 479 TABLE 314 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 480 TABLE 315 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 480 TABLE 316 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 480 TABLE 317 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 481 TABLE 318 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 481 TABLE 319 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 481 TABLE 320 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 482 TABLE 321 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 482 TABLE 322 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 482 TABLE 323 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 483 TABLE 324 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 483 TABLE 325 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 483 TABLE 326 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 484 TABLE 327 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 484 TABLE 328 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 484 TABLE 329 NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 485 TABLE 330 US: KEY MACROINDICATORS 486 TABLE 331 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 486 TABLE 332 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 487 TABLE 333 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 487 TABLE 334 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY MATERIAL, 2024-2031 (USD BILLION) 487 TABLE 335 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, BY USABILITY, 2024-2031 (USD BILLION) 488 TABLE 336 US PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2024-2031 (USD BILLION) 488 TABLE 337 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 488 TABLE 338 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 489 TABLE 339 US PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 489 TABLE 340 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 489 TABLE 341 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 490 TABLE 342 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 490 TABLE 343 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 490 TABLE 344 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 491 TABLE 345 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 491 TABLE 346 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 491 TABLE 347 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 492 TABLE 348 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 492 TABLE 349 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 492 TABLE 350 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 493 TABLE 351 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 493 TABLE 352 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 493 TABLE 353 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 494 TABLE 354 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 494 TABLE 355 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 494 TABLE 356 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 495 TABLE 357 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 495 TABLE 358 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 495 TABLE 359 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 496 TABLE 360 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 496 TABLE 361 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRAN SMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 496 TABLE 362 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 497 TABLE 363 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 497 TABLE 364 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 497 TABLE 365 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 498 TABLE 366 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 498 TABLE 367 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 498 TABLE 368 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 499 TABLE 369 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 499 TABLE 370 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 499 TABLE 371 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 500 TABLE 372 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 500 TABLE 373 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 500 TABLE 374 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 501 TABLE 375 US PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 501 TABLE 376 CANADA: KEY MACROINDICATORS 502 TABLE 377 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 503 TABLE 378 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 503 TABLE 379 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 504 TABLE 380 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 504 TABLE 381 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 504 TABLE 382 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 505 TABLE 383 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 505 TABLE 384 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 505 TABLE 385 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 506 TABLE 386 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 506 TABLE 387 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 506 TABLE 388 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 507 TABLE 389 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 507 TABLE 390 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 507 TABLE 391 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 508 TABLE 392 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 508 TABLE 393 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 508 TABLE 394 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 509 TABLE 395 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 509 TABLE 396 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 509 TABLE 397 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 510 TABLE 398 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 510 TABLE 399 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 510 TABLE 400 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 511 TABLE 401 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 511 TABLE 402 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 511 TABLE 403 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 512 TABLE 404 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 512 TABLE 405 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 512 TABLE 406 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 513 TABLE 407 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 513 TABLE 408 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 513 TABLE 409 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 514 TABLE 410 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 514 TABLE 411 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 514 TABLE 412 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 515 TABLE 413 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 515 TABLE 414 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 515 TABLE 415 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 516 TABLE 416 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 516 TABLE 417 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 516 TABLE 418 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 517 TABLE 419 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 517 TABLE 420 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 517 TABLE 421 CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 518 TABLE 422 EUROPE: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS) 519 TABLE 423 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024- 2031 (USD BILLION) 520 TABLE 424 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PRODUCT, 2024- 2031 (USD BILLION) 520 TABLE 425 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 521 TABLE 426 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 521 TABLE 427 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 521 TABLE 428 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 522 TABLE 429 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 522 TABLE 430 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 522 TABLE 431 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 523 TABLE 432 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 523 TABLE 433 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 523 TABLE 434 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 524 TABLE 435 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 524 TABLE 436 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 524 TABLE 437 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 525 TABLE 438 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 525 TABLE 439 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 525 TABLE 440 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 526 TABLE 441 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 526 TABLE 442 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 526 TABLE 443 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 527 TABLE 444 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 527 TABLE 445 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 527 TABLE 446 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 528 TABLE 447 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 528 TABLE 448 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 528 TABLE 449 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 529 TABLE 450 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 529 TABLE 451 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 529 TABLE 452 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 530 TABLE 453 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 530 TABLE 454 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 530 TABLE 455 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 531 TABLE 456 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 531 TABLE 457 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 531 TABLE 458 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 532 TABLE 459 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 532 TABLE 460 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 532 TABLE 461 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 533 TABLE 462 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 533 TABLE 463 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 533 TABLE 464 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 534 TABLE 465 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 534 TABLE 466 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 534 TABLE 467 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 535 TABLE 468 EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 535 TABLE 469 GERMANY: KEY MACROINDICATORS 537 TABLE 470 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 537 TABLE 471 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 537 TABLE 472 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 538 TABLE 473 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET,BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 538 TABLE 474 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 538 TABLE 475 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 539 TABLE 476 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 539 TABLE 477 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 539 TABLE 478 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 540 TABLE 479 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 540 TABLE 480 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 540 TABLE 481 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 541 TABLE 482 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 541 TABLE 483 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 541 TABLE 484 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 542 TABLE 485 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 542 TABLE 486 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 542 TABLE 487 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 543 TABLE 488 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 543 TABLE 489 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 543 TABLE 490 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 544 TABLE 491 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 544 TABLE 492 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 544 TABLE 493 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 545 TABLE 494 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 545 TABLE 495 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 545 TABLE 496 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 546 TABLE 497 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 546 TABLE 498 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 546 TABLE 499 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 547 TABLE 500 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 547 TABLE 501 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 547 TABLE 502 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 548 TABLE 503 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 548 TABLE 504 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 548 TABLE 505 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 549 TABLE 506 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 549 TABLE 507 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 549 TABLE 508 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 550 TABLE 509 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 550 TABLE 510 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 550 TABLE 511 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 551 TABLE 512 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 551 TABLE 513 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 551 TABLE 514 GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 552 TABLE 515 KEY MARKET INDICATORS: UK 553 TABLE 516 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024- 2031 (USD BILLION) 553 TABLE 517 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024- 2031 (USD BILLION) 553 TABLE 518 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 554 TABLE 519 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 554 TABLE 520 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 554 TABLE 521 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 555 TABLE 522 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 555 TABLE 523 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 555 TABLE 524 UK PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 556 TABLE 525 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 556 TABLE 526 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024- 2031 (USD BILLION) 556 TABLE 527 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024- 2031 (USD BILLION) 557 TABLE 528 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 557 TABLE 529 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 557 TABLE 530 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 558 TABLE 531 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 558 TABLE 532 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 558 TABLE 533 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 559 TABLE 534 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 559 TABLE 535 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 559 TABLE 536 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 560 TABLE 537 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024- 2031 (USD BILLION) 560 TABLE 538 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 560 TABLE 539 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024- 2031 (USD BILLION) 561 TABLE 540 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 561 TABLE 541 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 561 TABLE 542 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 562 TABLE 543 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 562 TABLE 544 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 562 TABLE 545 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 563 TABLE 546 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 563 TABLE 547 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 563 TABLE 548 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 564 TABLE 549 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 564 TABLE 550 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 564 TABLE 551 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 565 TABLE 552 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 565 TABLE 553 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 565 TABLE 554 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 566 TABLE 555 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 566 TABLE 556 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 566 TABLE 557 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 567 TABLE 558 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 567 TABLE 559 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 567 TABLE 560 UK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 568 TABLE 561 FRANCE: KEY MACROINDICATORS 569 TABLE 562 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 569 TABLE 563 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 569 TABLE 564 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 570 TABLE 565 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 570 TABLE 566 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 570 TABLE 567 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 571 TABLE 568 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 571 TABLE 569 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 571 TABLE 570 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 572 TABLE 571 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 572 TABLE 572 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 572 TABLE 573 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 573 TABLE 574 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 573 TABLE 575 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 573 TABLE 576 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 574 TABLE 577 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 574 TABLE 578 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 574 TABLE 579 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 575 TABLE 580 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 575 TABLE 581 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 575 TABLE 582 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 576 TABLE 583 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 576 TABLE 584 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 576 TABLE 585 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 577 TABLE 586 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 577 TABLE 587 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 577 TABLE 588 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 578 TABLE 589 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 578 TABLE 590 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 578 TABLE 591 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 579 TABLE 592 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 579 TABLE 593 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 579 TABLE 594 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 580 TABLE 595 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 580 TABLE 596 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 580 TABLE 597 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 581 TABLE 598 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 581 TABLE 599 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 581 TABLE 600 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 582 TABLE 601 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 582 TABLE 602 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 582 TABLE 603 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 583 TABLE 604 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 583 TABLE 605 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 583 TABLE 606 FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 584 TABLE 607 ITALY: KEY MACROINDICATORS 585 TABLE 608 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 585 TABLE 609 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 585 TABLE 610 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 586 TABLE 611 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 586 TABLE 612 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 586 TABLE 613 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 587 TABLE 614 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 587 TABLE 615 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 587 TABLE 616 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 588 TABLE 617 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 588 TABLE 618 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 588 TABLE 619 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 589 TABLE 620 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 589 TABLE 621 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 589 TABLE 622 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 590 TABLE 623 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 590 TABLE 624 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 590 TABLE 625 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 591 TABLE 626 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 591 TABLE 627 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 591 TABLE 628 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 592 TABLE 629 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 592 TABLE 630 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 592 TABLE 631 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 593 TABLE 632 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 593 TABLE 633 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 593 TABLE 634 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 594 TABLE 635 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 594 TABLE 636 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 594 TABLE 637 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 595 TABLE 638 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 595 TABLE 639 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 595 TABLE 640 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 596 TABLE 641 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 596 TABLE 642 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 596 TABLE 643 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 597 TABLE 644 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 597 TABLE 645 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 597 TABLE 646 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 598 TABLE 647 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 598 TABLE 648 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 598 TABLE 649 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 599 TABLE 650 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 599 TABLE 651 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 599 TABLE 652 ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 600 TABLE 653 DENMARK: KEY MACROINDICATORS 600 TABLE 654 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 601 TABLE 655 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 601 TABLE 656 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 601 TABLE 657 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 602 TABLE 658 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 602 TABLE 659 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 602 TABLE 660 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 603 TABLE 661 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 603 TABLE 662 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 603 TABLE 663 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 604 TABLE 664 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 604 TABLE 665 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 604 TABLE 666 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 605 TABLE 667 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 605 TABLE 668 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 605 TABLE 669 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 606 TABLE 670 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 606 TABLE 671 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 606 TABLE 672 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 607 TABLE 673 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 607 TABLE 674 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 607 TABLE 675 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 608 TABLE 676 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 608 TABLE 677 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 608 TABLE 678 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 609 TABLE 679 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 609 TABLE 680 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 609 TABLE 681 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 610 TABLE 682 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 610 TABLE 683 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 610 TABLE 684 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 611 TABLE 685 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 611 TABLE 686 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 611 TABLE 687 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 612 TABLE 688 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 612 TABLE 689 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 612 TABLE 690 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 613 TABLE 691 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 613 TABLE 692 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 613 TABLE 693 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 614 TABLE 694 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 614 TABLE 695 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 614 TABLE 696 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 615 TABLE 697 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 615 TABLE 698 DENMARK PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 615 TABLE 699 SWEDEN: KEY MACROINDICATORS 616 TABLE 700 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 616 TABLE 701 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 617 TABLE 702 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 617 TABLE 703 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 617 TABLE 704 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 618 TABLE 705 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 618 TABLE 706 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 618 TABLE 707 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 619 TABLE 708 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 619 TABLE 709 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 619 TABLE 710 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 620 TABLE 711 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 620 TABLE 712 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 620 TABLE 713 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 621 TABLE 714 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 621 TABLE 715 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 621 TABLE 716 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 622 TABLE 717 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 622 TABLE 718 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 622 TABLE 719 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 623 TABLE 720 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 623 TABLE 721 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 623 TABLE 722 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 624 TABLE 723 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 624 TABLE 724 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 624 TABLE 725 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 625 TABLE 726 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 625 TABLE 727 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 625 TABLE 728 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 626 TABLE 729 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 626 TABLE 730 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 626 TABLE 731 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 627 TABLE 732 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 627 TABLE 733 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 627 TABLE 734 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 628 TABLE 735 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 628 TABLE 736 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 628 TABLE 737 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 629 TABLE 738 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 629 TABLE 739 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 629 TABLE 740 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 630 TABLE 741 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 630 TABLE 742 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 630 TABLE 743 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 631 TABLE 744 SWEDEN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 631 TABLE 745 SPAIN: KEY MACROINDICATORS 632 TABLE 746 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 632 TABLE 747 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 633 TABLE 748 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 633 TABLE 749 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 633 TABLE 750 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 634 TABLE 751 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 634 TABLE 752 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 634 TABLE 753 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 635 TABLE 754 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 635 TABLE 755 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 635 TABLE 756 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 636 TABLE 757 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 636 TABLE 758 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 636 TABLE 759 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 637 TABLE 760 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 637 TABLE 761 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 637 TABLE 762 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 638 TABLE 763 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 638 TABLE 764 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 638 TABLE 765 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 639 TABLE 766 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 639 TABLE 767 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 639 TABLE 768 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 640 TABLE 769 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 640 TABLE 770 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 640 TABLE 771 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 641 TABLE 772 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 641 TABLE 773 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 641 TABLE 774 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 642 TABLE 775 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 642 TABLE 776 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 642 TABLE 777 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 643 TABLE 778 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 643 TABLE 779 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 643 TABLE 780 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 644 TABLE 781 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 644 TABLE 782 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 644 TABLE 783 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 645 TABLE 784 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 645 TABLE 785 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 645 TABLE 786 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 646 TABLE 787 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 646 TABLE 788 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 646 TABLE 789 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 647 TABLE 790 SPAIN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 647 TABLE 791 NETHERLANDS: KEY MACROINDICATORS 648 TABLE 792 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 649 TABLE 793 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 649 TABLE 794 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 649 TABLE 795 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET,BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 650 TABLE 796 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 650 TABLE 797 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 650 TABLE 798 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 651 TABLE 799 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 651 TABLE 800 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 651 TABLE 801 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 652 TABLE 802 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 652 TABLE 803 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 652 TABLE 804 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 653 TABLE 805 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 653 TABLE 806 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 653 TABLE 807 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 654 TABLE 808 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 654 TABLE 809 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 654 TABLE 810 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 655 TABLE 811 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 655 TABLE 812 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 655 TABLE 813 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 656 TABLE 814 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 656 TABLE 815 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 656 TABLE 816 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 657 TABLE 817 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 657 TABLE 818 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 657 TABLE 819 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 658 TABLE 820 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 658 TABLE 821 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 658 TABLE 822 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 659 TABLE 823 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 659 TABLE 824 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 659 TABLE 825 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 660 TABLE 826 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 660 TABLE 827 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 660 TABLE 828 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 661 TABLE 829 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 661 TABLE 830 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 661 TABLE 831 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 662 TABLE 832 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 662 TABLE 833 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 662 TABLE 834 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 663 TABLE 835 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 663 TABLE 836 NETHERLANDS PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 663 TABLE 837 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 664 TABLE 838 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 665 TABLE 839 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 665 TABLE 840 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COMPUTED TOMOGRAPHY IMAGING SYSTEMS, 2024-2031 (USD BILLION) 665 TABLE 841 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 666 TABLE 842 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 666 TABLE 843 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 666 TABLE 844 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 667 TABLE 845 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 667 TABLE 846 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 667 TABLE 847 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 668 TABLE 848 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 668 TABLE 849 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 668 TABLE 850 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 669 TABLE 851 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 669 TABLE 852 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 669 TABLE 853 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 670 TABLE 854 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 670 TABLE 855 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 670 TABLE 856 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 671 TABLE 857 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 671 TABLE 858 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 671 TABLE 859 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 672 TABLE 860 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 672 TABLE 861 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 672 TABLE 862 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 673 TABLE 863 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 673 TABLE 864 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 673 TABLE 865 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 674 TABLE 866 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 674 TABLE 867 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 674 TABLE 868 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 675 TABLE 869 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 675 TABLE 870 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 675 TABLE 871 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 676 TABLE 872 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 676 TABLE 873 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 676 TABLE 874 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 677 TABLE 875 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 677 TABLE 876 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 677 TABLE 877 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 678 TABLE 878 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 678 TABLE 879 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 678 TABLE 880 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 679 TABLE 881 REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 679 TABLE 882 ASIA PACIFIC: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS) 681 TABLE 883 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024- 2031 (USD BILLION) 682 TABLE 884 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 682 TABLE 885 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 683 TABLE 886 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 683 TABLE 887 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 683 TABLE 888 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 684 TABLE 889 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 684 TABLE 890 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 684 TABLE 891 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 685 TABLE 892 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 685 TABLE 893 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 685 TABLE 894 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 686 TABLE 895 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 686 TABLE 896 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 686 TABLE 897 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 687 TABLE 898 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 687 TABLE 899 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 687 TABLE 900 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 688 TABLE 901 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 688 TABLE 902 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 688 TABLE 903 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 689 TABLE 904 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 689 TABLE 905 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024- 2031 (USD BILLION) 689 TABLE 906 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 690 TABLE 907 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024- 2031 (USD BILLION) 690 TABLE 908 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 690 TABLE 909 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 691 TABLE 910 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 691 TABLE 911 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 691 TABLE 912 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 692 TABLE 913 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 692 TABLE 914 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 692 TABLE 915 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024- 2031 (USD BILLION) 693 TABLE 916 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 693 TABLE 917 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 693 TABLE 918 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 694 TABLE 919 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 694 TABLE 920 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 694 TABLE 921 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 695 TABLE 922 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 695 TABLE 923 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 695 TABLE 924 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 696 TABLE 925 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 696 TABLE 926 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 696 TABLE 927 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024- 2031 (USD BILLION) 697 TABLE 928 ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 697 TABLE 929 CHINA: KEY MACROINDICATORS 699 TABLE 930 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 699 TABLE 931 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 699 TABLE 932 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 700 TABLE 933 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 700 TABLE 934 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 700 TABLE 935 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 701 TABLE 936 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 701 TABLE 937 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 701 TABLE 938 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 702 TABLE 939 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 702 TABLE 940 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 702 TABLE 941 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 703 TABLE 942 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 703 TABLE 943 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 703 TABLE 944 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 704 TABLE 945 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 704 TABLE 946 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 704 TABLE 947 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 705 TABLE 948 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 705 TABLE 949 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 705 TABLE 950 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 706 TABLE 951 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 706 TABLE 952 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 706 TABLE 953 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 707 TABLE 954 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 707 TABLE 955 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 707 TABLE 956 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 708 TABLE 957 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 708 TABLE 958 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 708 TABLE 959 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 709 TABLE 960 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 709 TABLE 961 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 709 TABLE 962 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 710 TABLE 963 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 710 TABLE 964 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 710 TABLE 965 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 711 TABLE 966 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 711 TABLE 967 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 711 TABLE 968 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 712 TABLE 969 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 712 TABLE 970 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 712 TABLE 971 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 713 TABLE 972 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 713 TABLE 973 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 713 TABLE 974 CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 714 TABLE 975 JAPAN: KEY MACROINDICATORS 715 TABLE 976 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PRODUCT, 2024- 2031 (USD BILLION) 716 TABLE 977 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 716 TABLE 978 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 716 TABLE 979 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 717 TABLE 980 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 717 TABLE 981 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 717 TABLE 982 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 718 TABLE 983 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 718 TABLE 984 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 718 TABLE 985 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 719 TABLE 986 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 719 TABLE 987 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 719 TABLE 988 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 720 TABLE 989 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 720 TABLE 990 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 720 TABLE 991 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 721 TABLE 992 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 721 TABLE 993 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 721 TABLE 994 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 722 TABLE 995 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 722 TABLE 996 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 722 TABLE 997 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 723 TABLE 998 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 723 TABLE 999 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 723 TABLE 1000 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 724 TABLE 1001 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 724 TABLE 1002 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 724 TABLE 1003 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 725 TABLE 1004 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 725 TABLE 1005 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 725 TABLE 1006 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 726 TABLE 1007 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 726 TABLE 1008 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 726 TABLE 1009 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 727 TABLE 1010 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 727 TABLE 1011 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 727 TABLE 1012 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 728 TABLE 1013 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 728 TABLE 1014 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 728 TABLE 1015 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 729 TABLE 1016 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 729 TABLE 1017 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 729 TABLE 1018 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 730 TABLE 1019 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 730 TABLE 1020 JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 730 TABLE 1021 INDIA: KEY MACROINDICATORS 731 TABLE 1022 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 732 TABLE 1023 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 732 TABLE 1024 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 732 TABLE 1025 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 733 TABLE 1026 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 733 TABLE 1027 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 733 TABLE 1028 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024- 2031 (USD BILLION) 734 TABLE 1029 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 734 TABLE 1030 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 734 TABLE 1031 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 735 TABLE 1032 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 735 TABLE 1033 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 735 TABLE 1034 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 736 TABLE 1035 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 736 TABLE 1036 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 736 TABLE 1037 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 737 TABLE 1038 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 737 TABLE 1039 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 737 TABLE 1040 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 738 TABLE 1041 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 738 TABLE 1042 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 738 TABLE 1043 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 739 TABLE 1044 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 739 TABLE 1045 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 739 TABLE 1046 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 740 TABLE 1047 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 740 TABLE 1048 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 740 TABLE 1049 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 741 TABLE 1050 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 741 TABLE 1051 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 741 TABLE 1052 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 742 TABLE 1053 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 742 TABLE 1054 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 742 TABLE 1055 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 743 TABLE 1056 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 743 TABLE 1057 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 744 TABLE 1058 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 744 TABLE 1059 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 744 TABLE 1060 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 745 TABLE 1061 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 745 TABLE 1062 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 745 TABLE 1063 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 746 TABLE 1064 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 746 TABLE 1065 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 746 TABLE 1066 INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 747 TABLE 1067 AUSTRALIA: KEY MACROINDICATORS 748 TABLE 1068 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 748 TABLE 1069 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 749 TABLE 1070 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 749 TABLE 1071 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 749 TABLE 1072 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 750 TABLE 1073 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 750 TABLE 1074 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 750 TABLE 1075 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 751 TABLE 1076 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 751 TABLE 1077 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 751 TABLE 1078 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 752 TABLE 1079 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 752 TABLE 1080 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 752 TABLE 1081 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 753 TABLE 1082 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 753 TABLE 1083 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 753 TABLE 1084 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 754 TABLE 1085 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 754 TABLE 1086 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 754 TABLE 1087 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 755 TABLE 1088 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 755 TABLE 1089 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 755 TABLE 1090 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 756 TABLE 1091 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 756 TABLE 1092 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 756 TABLE 1093 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 757 TABLE 1094 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 757 TABLE 1095 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 757 TABLE 1096 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 758 TABLE 1097 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 758 TABLE 1098 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 758 TABLE 1099 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 759 TABLE 1100 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 759 TABLE 1101 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 759 TABLE 1102 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 760 TABLE 1103 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 760 TABLE 1104 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 760 TABLE 1105 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 761 TABLE 1106 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 761 TABLE 1107 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 761 TABLE 1108 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 762 TABLE 1109 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 762 TABLE 1110 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 762 TABLE 1111 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 763 TABLE 1112 AUSTRALIA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 763 TABLE 1113 SOUTH KOREA: KEY MACROINDICATORS 764 TABLE 1114 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 764 TABLE 1115 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 765 TABLE 1116 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 765 TABLE 1117 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 765 TABLE 1118 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 766 TABLE 1119 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 766 TABLE 1120 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 766 TABLE 1121 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 767 TABLE 1122 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 767 TABLE 1123 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 767 TABLE 1124 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 768 TABLE 1125 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 768 TABLE 1126 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 768 TABLE 1127 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 769 TABLE 1128 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 769 TABLE 1129 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 769 TABLE 1130 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 770 TABLE 1131 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 770 TABLE 1132 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 770 TABLE 1133 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 771 TABLE 1134 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 771 TABLE 1135 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 771 TABLE 1136 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 772 TABLE 1137 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 772 TABLE 1138 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 772 TABLE 1139 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 773 TABLE 1140 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 773 TABLE 1141 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 773 TABLE 1142 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 774 TABLE 1143 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 774 TABLE 1144 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 774 TABLE 1145 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 775 TABLE 1146 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 775 TABLE 1147 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 775 TABLE 1148 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 776 TABLE 1149 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 776 TABLE 1150 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 776 TABLE 1151 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 777 TABLE 1152 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 777 TABLE 1153 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 777 TABLE 1154 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 778 TABLE 1155 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 778 TABLE 1156 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 778 TABLE 1157 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 779 TABLE 1158 SOUTH KOREA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 779 TABLE 1159 NEW ZEALAND: KEY MACROINDICATORS 780 TABLE 1160 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 780 TABLE 1161 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 781 TABLE 1162 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 781 TABLE 1163 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 781 TABLE 1164 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 782 TABLE 1165 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 782 TABLE 1166 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 782 TABLE 1167 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 783 TABLE 1168 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 783 TABLE 1169 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 783 TABLE 1170 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 784 TABLE 1171 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 784 TABLE 1172 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 784 TABLE 1173 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 785 TABLE 1174 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 785 TABLE 1175 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 785 TABLE 1176 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 786 TABLE 1177 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 786 TABLE 1178 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 786 TABLE 1179 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 787 TABLE 1180 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 787 TABLE 1181 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 787 TABLE 1182 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 788 TABLE 1183 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 788 TABLE 1184 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 788 TABLE 1185 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 789 TABLE 1186 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 789 TABLE 1187 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 789 TABLE 1188 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 790 TABLE 1189 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 790 TABLE 1190 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 790 TABLE 1191 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 791 TABLE 1192 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 791 TABLE 1193 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 791 TABLE 1194 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 792 TABLE 1195 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 792 TABLE 1196 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 792 TABLE 1197 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 793 TABLE 1198 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 793 TABLE 1199 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 793 TABLE 1200 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 794 TABLE 1201 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 794 TABLE 1202 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 794 TABLE 1203 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 795 TABLE 1204 NEW ZEALAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 795 TABLE 1205 THAILAND: KEY MACROINDICATORS 796 TABLE 1206 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 796 TABLE 1207 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 797 TABLE 1208 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 797 TABLE 1209 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 797 TABLE 1210 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 798 TABLE 1211 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 798 TABLE 1212 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 798 TABLE 1213 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 799 TABLE 1214 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 799 TABLE 1215 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 799 TABLE 1216 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 800 TABLE 1217 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 800 TABLE 1218 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 800 TABLE 1219 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 801 TABLE 1220 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 801 TABLE 1221 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 801 TABLE 1222 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 802 TABLE 1223 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 802 TABLE 1224 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 802 TABLE 1225 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 803 TABLE 1226 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 803 TABLE 1227 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 803 TABLE 1228 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 804 TABLE 1229 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 804 TABLE 1230 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 804 TABLE 1231 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 805 TABLE 1232 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 805 TABLE 1233 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 805 TABLE 1234 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 806 TABLE 1235 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 806 TABLE 1236 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 806 TABLE 1237 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 807 TABLE 1238 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 807 TABLE 1239 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 807 TABLE 1240 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 808 TABLE 1241 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 808 TABLE 1242 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 808 TABLE 1243 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 809 TABLE 1244 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 809 TABLE 1245 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 809 TABLE 1246 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 810 TABLE 1247 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 810 TABLE 1248 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 810 TABLE 1249 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 811 TABLE 1250 THAILAND PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 811 TABLE 1251 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 813 TABLE 1252 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 813 TABLE 1253 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 813 TABLE 1254 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 814 TABLE 1255 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 814 TABLE 1256 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 814 TABLE 1257 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 815 TABLE 1258 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 815 TABLE 1259 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 815 TABLE 1260 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 816 TABLE 1261 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 816 TABLE 1262 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 816 TABLE 1263 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 817 TABLE 1264 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 817 TABLE 1265 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 817 TABLE 1266 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 818 TABLE 1267 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 818 TABLE 1268 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 818 TABLE 1269 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 819 TABLE 1270 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 819 TABLE 1271 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 819 TABLE 1272 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 820 TABLE 1273 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 820 TABLE 1274 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 820 TABLE 1275 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 821 TABLE 1276 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 821 TABLE 1277 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 821 TABLE 1278 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 822 TABLE 1279 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 822 TABLE 1280 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 822 TABLE 1281 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 823 TABLE 1282 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 823 TABLE 1283 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 823 TABLE 1284 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 824 TABLE 1285 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 824 TABLE 1286 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 825 TABLE 1287 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 825 TABLE 1288 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 825 TABLE 1289 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 826 TABLE 1290 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 826 TABLE 1291 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 826 TABLE 1292 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 827 TABLE 1293 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 827 TABLE 1294 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024- 2031 (USD BILLION) 827 TABLE 1295 REST OF ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 828 TABLE 1296 LATIN AMERICA: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024-2031 (TEN THOUSAND UNITS) 829 TABLE 1297 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024- 2031 (USD BILLION) 830 TABLE 1298 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 830 TABLE 1299 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 831 TABLE 1300 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 831 TABLE 1301 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 831 TABLE 1302 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 832 TABLE 1303 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 832 TABLE 1304 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 832 TABLE 1305 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 833 TABLE 1306 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 833 TABLE 1307 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 833 TABLE 1308 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 834 TABLE 1309 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 834 TABLE 1310 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 834 TABLE 1311 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 835 TABLE 1312 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 835 TABLE 1313 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 835 TABLE 1314 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 836 TABLE 1315 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 836 TABLE 1316 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 836 TABLE 1317 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 837 TABLE 1318 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 837 TABLE 1319 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 837 TABLE 1320 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 838 TABLE 1321 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 838 TABLE 1322 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 838 TABLE 1323 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 839 TABLE 1324 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 839 TABLE 1325 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 839 TABLE 1326 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 840 TABLE 1327 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 840 TABLE 1328 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 840 TABLE 1329 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 841 TABLE 1330 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 841 TABLE 1331 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 841 TABLE 1332 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 842 TABLE 1333 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 842 TABLE 1334 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 842 TABLE 1335 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 843 TABLE 1336 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 843 TABLE 1337 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 843 TABLE 1338 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 844 TABLE 1339 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 844 TABLE 1340 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 844 TABLE 1341 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 845 TABLE 1342 LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 845 TABLE 1343 BRAZIL: KEY MACROINDICATORS 846 TABLE 1344 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 847 TABLE 1345 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 847 TABLE 1346 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 847 TABLE 1347 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 848 TABLE 1348 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 848 TABLE 1349 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 848 TABLE 1350 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 849 TABLE 1351 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 849 TABLE 1352 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 849 TABLE 1353 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 850 TABLE 1354 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 850 TABLE 1355 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 850 TABLE 1356 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 851 TABLE 1357 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 851 TABLE 1358 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 851 TABLE 1359 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 852 TABLE 1360 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 852 TABLE 1361 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 852 TABLE 1362 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024- 2031 (USD BILLION) 853 TABLE 1363 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024- 2031 (USD BILLION) 853 TABLE 1364 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 853 TABLE 1365 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 854 TABLE 1366 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 854 TABLE 1367 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 854 TABLE 1368 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 855 TABLE 1369 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 855 TABLE 1370 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 855 TABLE 1371 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 856 TABLE 1372 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 856 TABLE 1373 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 856 TABLE 1374 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 857 TABLE 1375 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 857 TABLE 1376 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024- 2031 (USD BILLION) 857 TABLE 1377 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 858 TABLE 1378 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 858 TABLE 1379 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 859 TABLE 1380 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 859 TABLE 1381 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 859 TABLE 1382 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 860 TABLE 1383 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 860 TABLE 1384 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 860 TABLE 1385 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 861 TABLE 1386 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024- 2031 (USD BILLION) 861 TABLE 1387 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 861 TABLE 1388 BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 862 TABLE 1389 MEXICO: KEY MACROINDICATORS 863 TABLE 1390 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD BILLION) 863 TABLE 1391 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 863 TABLE 1392 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024-2031 (USD BILLION) 864 TABLE 1393 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 864 TABLE 1394 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 864 TABLE 1395 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 865 TABLE 1396 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 865 TABLE 1397 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 865 TABLE 1398 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 866 TABLE 1399 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024- 2031 (USD BILLION) 866 TABLE 1400 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 866 TABLE 1401 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 867 TABLE 1402 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 867 TABLE 1403 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 867 TABLE 1404 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 868 TABLE 1405 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 868 TABLE 1406 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 868 TABLE 1407 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 869 TABLE 1408 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 869 TABLE 1409 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 869 TABLE 1410 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024- 2031 (USD BILLION) 870 TABLE 1411 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 870 TABLE 1412 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024- 2031 (USD BILLION) 870 TABLE 1413 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 871 TABLE 1414 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 871 TABLE 1415 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 871 TABLE 1416 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024- 2031 (USD BILLION) 872 TABLE 1417 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 872 TABLE 1418 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 872 TABLE 1419 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 873 TABLE 1420 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 873 TABLE 1421 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 873 TABLE 1422 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 874 TABLE 1423 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 874 TABLE 1424 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 874 TABLE 1425 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 875 TABLE 1426 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 875 TABLE 1427 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 875 TABLE 1428 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 876 TABLE 1429 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 876 TABLE 1430 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 876 TABLE 1431 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 877 TABLE 1432 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 877 TABLE 1433 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 877 TABLE 1434 MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 878 TABLE 1435 ARGENTINA: KEY MACROINDICATORS 878 TABLE 1436 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 879 TABLE 1437 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 879 TABLE 1438 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 879 TABLE 1439 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 880 TABLE 1440 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 880 TABLE 1441 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 880 TABLE 1442 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 881 TABLE 1443 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 881 TABLE 1444 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 881 TABLE 1445 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 882 TABLE 1446 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 882 TABLE 1447 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 882 TABLE 1448 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 883 TABLE 1449 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 883 TABLE 1450 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 883 TABLE 1451 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 884 TABLE 1452 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 884 TABLE 1453 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 884 TABLE 1454 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 885 TABLE 1455 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 885 TABLE 1456 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 885 TABLE 1457 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 886 TABLE 1458 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 886 TABLE 1459 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 886 TABLE 1460 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 887 TABLE 1461 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 887 TABLE 1462 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 887 TABLE 1463 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 888 TABLE 1464 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 888 TABLE 1465 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 888 TABLE 1466 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 889 TABLE 1467 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 889 TABLE 1468 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 889 TABLE 1469 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 890 TABLE 1470 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 890 TABLE 1471 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 890 TABLE 1472 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 891 TABLE 1473 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 891 TABLE 1474 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 891 TABLE 1475 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 892 TABLE 1476 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 892 TABLE 1477 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 892 TABLE 1478 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 893 TABLE 1479 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 893 TABLE 1480 ARGENTINA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 893 TABLE 1481 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 894 TABLE 1482 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 895 TABLE 1483 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 895 TABLE 1484 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 895 TABLE 1485 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 896 TABLE 1486 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 896 TABLE 1487 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 896 TABLE 1488 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 897 TABLE 1489 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 897 TABLE 1490 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 897 TABLE 1491 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 898 TABLE 1492 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 898 TABLE 1493 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 898 TABLE 1494 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 899 TABLE 1495 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 899 TABLE 1496 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 899 TABLE 1497 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 900 TABLE 1498 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 900 TABLE 1499 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 900 TABLE 1500 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 901 TABLE 1501 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 901 TABLE 1502 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 901 TABLE 1503 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 902 TABLE 1504 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 902 TABLE 1505 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 902 TABLE 1506 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 903 TABLE 1507 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 903 TABLE 1508 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 903 TABLE 1509 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 904 TABLE 1510 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 904 TABLE 1511 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 904 TABLE 1512 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 905 TABLE 1513 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 905 TABLE 1514 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 905 TABLE 1515 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 906 TABLE 1516 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 906 TABLE 1517 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 906 TABLE 1518 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 907 TABLE 1519 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 907 TABLE 1520 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 907 TABLE 1521 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 908 TABLE 1522 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 908 TABLE 1523 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 908 TABLE 1524 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 909 TABLE 1525 REST OF LATIN AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 909 TABLE 1526 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICES, 2024–2031 (TEN THOUSAND UNITS) 911 TABLE 1527 MIDDLE EAST & AFRICA MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 911 TABLE 1528 MEA MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PRODUCT, 2024–2031 (USD BILLION) 912 TABLE 1529 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 912 TABLE 1530 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 913 TABLE 1531 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 913 TABLE 1532 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 913 TABLE 1533 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 914 TABLE 1534 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 914 TABLE 1535 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 914 TABLE 1536 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 915 TABLE 1537 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 915 TABLE 1538 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 915 TABLE 1539 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 916 TABLE 1540 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 916 TABLE 1541 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 916 TABLE 1542 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 917 TABLE 1543 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 917 TABLE 1544 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 917 TABLE 1545 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 918 TABLE 1546 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 918 TABLE 1547 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 918 TABLE 1548 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 919 TABLE 1549 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 919 TABLE 1550 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 919 TABLE 1551 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 920 TABLE 1552 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 920 TABLE 1553 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 920 TABLE 1554 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 921 TABLE 1555 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 921 TABLE 1556 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 921 TABLE 1557 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 922 TABLE 1558 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 922 TABLE 1559 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 922 TABLE 1560 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 923 TABLE 1561 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 923 TABLE 1562 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 923 TABLE 1563 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 924 TABLE 1564 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 924 TABLE 1565 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 924 TABLE 1566 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 925 TABLE 1567 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 925 TABLE 1568 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 925 TABLE 1569 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 926 TABLE 1570 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 926 TABLE 1571 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 926 TABLE 1572 MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 927 TABLE 1573 GCC GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2024–2031 (USD BILLION) 928 TABLE 1574 GCC GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 928 TABLE 1575 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 928 TABLE 1576 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 929 TABLE 1577 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 929 TABLE 1578 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 929 TABLE 1579 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 930 TABLE 1580 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 930 TABLE 1581 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 930 TABLE 1582 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 931 TABLE 1583 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 931 TABLE 1584 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 931 TABLE 1585 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 932 TABLE 1586 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 932 TABLE 1587 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 932 TABLE 1588 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 933 TABLE 1589 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 933 TABLE 1590 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 933 TABLE 1591 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 934 TABLE 1592 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 934 TABLE 1593 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 934 TABLE 1594 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 935 TABLE 1595 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 935 TABLE 1596 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 935 TABLE 1597 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 936 TABLE 1598 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 936 TABLE 1599 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 936 TABLE 1600 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 937 TABLE 1601 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 937 TABLE 1602 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 937 TABLE 1603 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 938 TABLE 1604 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 938 TABLE 1605 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 938 TABLE 1606 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 939 TABLE 1607 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 939 TABLE 1608 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 939 TABLE 1609 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 940 TABLE 1610 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 940 TABLE 1611 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 940 TABLE 1612 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 941 TABLE 1613 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 941 TABLE 1614 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 941 TABLE 1615 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 942 TABLE 1616 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 942 TABLE 1617 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 942 TABLE 1618 GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 943 TABLE 1619 KSA: KEY MACROINDICATORS 943 TABLE 1620 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 944 TABLE 1621 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 944 TABLE 1622 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 944 TABLE 1623 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 945 TABLE 1624 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 945 TABLE 1625 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 945 TABLE 1626 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 946 TABLE 1627 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 946 TABLE 1628 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 946 TABLE 1629 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 947 TABLE 1630 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 947 TABLE 1631 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 947 TABLE 1632 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 948 TABLE 1633 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 948 TABLE 1634 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 948 TABLE 1635 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 949 TABLE 1636 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 949 TABLE 1637 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 949 TABLE 1638 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 950 TABLE 1639 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 950 TABLE 1640 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 950 TABLE 1641 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 951 TABLE 1642 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 951 TABLE 1643 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 951 TABLE 1644 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 952 TABLE 1645 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 952 TABLE 1646 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 952 TABLE 1647 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 953 TABLE 1648 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 953 TABLE 1649 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 953 TABLE 1650 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 954 TABLE 1651 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 954 TABLE 1652 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 954 TABLE 1653 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 955 TABLE 1654 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 955 TABLE 1655 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 956 TABLE 1656 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 956 TABLE 1657 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 956 TABLE 1658 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 957 TABLE 1659 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 957 TABLE 1660 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 957 TABLE 1661 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 958 TABLE 1662 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 958 TABLE 1663 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 958 TABLE 1664 KINGDOM OF SAUDI ARABIA (KSA) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 959 TABLE 1665 UAE: KEY MACROINDICATORS 960 TABLE 1666 UAE UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 960 TABLE 1667 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 960 TABLE 1668 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 961 TABLE 1669 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 961 TABLE 1670 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 961 TABLE 1671 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 962 TABLE 1672 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 962 TABLE 1673 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 962 TABLE 1674 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 963 TABLE 1675 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 963 TABLE 1676 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 963 TABLE 1677 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 964 TABLE 1678 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 964 TABLE 1679 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 964 TABLE 1680 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 965 TABLE 1681 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 965 TABLE 1682 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 965 TABLE 1683 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 966 TABLE 1684 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 966 TABLE 1685 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 966 TABLE 1686 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 967 TABLE 1687 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 967 TABLE 1688 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 967 TABLE 1689 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 968 TABLE 1690 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 968 TABLE 1691 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 968 TABLE 1692 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 969 TABLE 1693 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 969 TABLE 1694 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 969 TABLE 1695 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 970 TABLE 1696 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 970 TABLE 1697 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 970 TABLE 1698 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 971 TABLE 1699 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 971 TABLE 1700 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 971 TABLE 1701 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 972 TABLE 1702 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 972 TABLE 1703 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 972 TABLE 1704 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 973 TABLE 1705 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 973 TABLE 1706 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 973 TABLE 1707 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 974 TABLE 1708 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 974 TABLE 1709 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 974 TABLE 1710 UNITED ARAB EMIRATES (UAE) PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 975 TABLE 1711 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 976 TABLE 1712 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 976 TABLE 1713 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 976 TABLE 1714 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024–2031 (USD BILLION) 977 TABLE 1715 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024–2031 (USD BILLION) 977 TABLE 1716 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024–2031 (USD BILLION) 977 TABLE 1717 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024–2031 (USD BILLION) 978 TABLE 1718 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024–2031 (USD BILLION) 978 TABLE 1719 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024–2031 (USD BILLION) 978 TABLE 1720 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024–2031 (USD BILLION) 979 TABLE 1721 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 979 TABLE 1722 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 979 TABLE 1723 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024–2031 (USD BILLION) 980 TABLE 1724 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024–2031 (USD BILLION) 980 TABLE 1725 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 980 TABLE 1726 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 981 TABLE 1727 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 981 TABLE 1728 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024–2031 (USD BILLION) 981 TABLE 1729 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024–2031 (USD BILLION) 982 TABLE 1730 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024–2031 (USD BILLION) 982 TABLE 1731 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024–2031 (USD BILLION) 982 TABLE 1732 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024–2031 (USD BILLION) 983 TABLE 1733 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024–2031 (USD BILLION) 983 TABLE 1734 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024–2031 (USD BILLION) 983 TABLE 1735 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024–2031 (USD BILLION) 984 TABLE 1736 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024–2031 (USD BILLION) 984 TABLE 1737 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024–2031 (USD BILLION) 984 TABLE 1738 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024–2031 (USD BILLION) 985 TABLE 1739 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024–2031 (USD BILLION) 985 TABLE 1740 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024–2031 (USD BILLION) 985 TABLE 1741 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024–2031 (USD BILLION) 986 TABLE 1742 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 986 TABLE 1743 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024–2031 (USD BILLION) 986 TABLE 1744 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 987 TABLE 1745 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 987 TABLE 1746 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 988 TABLE 1747 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 988 TABLE 1748 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 988 TABLE 1749 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 989 TABLE 1750 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 989 TABLE 1751 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 989 TABLE 1752 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024–2031 (USD BILLION) 990 TABLE 1753 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024–2031 (USD BILLION) 990 TABLE 1754 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024–2031 (USD BILLION) 990 TABLE 1755 REST OF GCC COUNTRIES PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024–2031 (USD BILLION) 991 TABLE 1756 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD BILLION) 992 TABLE 1757 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY, 2024–2031 (USD BILLION) 992 TABLE 1758 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES, 2024–2031 (USD BILLION) 992 TABLE 1759 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES MATERIAL, 2024-2031 (USD BILLION) 993 TABLE 1760 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES USABILITY, 2024-2031 (USD BILLION) 993 TABLE 1761 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY DEVICES TYPE, 2024-2031 (USD BILLION) 993 TABLE 1762 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SELF-INJECTION SYSTEMS, 2024-2031 (USD BILLION) 994 TABLE 1763 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY FORMULATIONS, 2024-2031 (USD BILLION) 994 TABLE 1764 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, INJECTABLE DRUG DELIVERY, BY FORMULATION PACKAGING, 2024-2031 (USD BILLION) 995 TABLE 1765 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY, 2024-2031 (USD BILLION) 995 TABLE 1766 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 995 TABLE 1767 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 996 TABLE 1768 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID ORAL FORMULATIONS, 2024-2031 (USD BILLION) 996 TABLE 1769 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY, 2024-2031 (USD BILLION) 996 TABLE 1770 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 997 TABLE 1771 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 997 TABLE 1772 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID TOPICAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 997 TABLE 1773 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSDERMAL DRUG FORMULATIONS, 2024-2031 (USD BILLION) 998 TABLE 1774 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DRUG DELIVERY, 2024-2031 (USD BILLION) 998 TABLE 1775 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR FORMULATIONS, 2024-2031 (USD BILLION) 998 TABLE 1776 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY LIQUID FORMULATIONS, 2024-2031 (USD BILLION) 999 TABLE 1777 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY SEMI-SOLID FORMULATIONS, 2024-2031 (USD BILLION) 999 TABLE 1778 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCULAR DEVICES, 2024-2031 (USD BILLION) 999 TABLE 1779 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2031 (USD BILLION) 1000 TABLE 1780 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY DEVICE, 2024-2031 (USD BILLION) 1000 TABLE 1781 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY FORMULATION, 2024-2031 (USD BILLION) 1000 TABLE 1782 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NEBULIZER, 2024-2031 (USD BILLION) 1001 TABLE 1783 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY, 2024-2031 (USD BILLION) 1001 TABLE 1784 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY, 2024-2031 (USD BILLION) 1001 TABLE 1785 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL TRANSMUCOSAL FORMULATIONS, 2024-2031 (USD BILLION) 1002 TABLE 1786 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES, 2024-2031 (USD BILLION) 1002 TABLE 1787 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY, 2024-2031 (USD BILLION) 1002 TABLE 1788 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY, 2024-2031 (USD BILLION) 1003 TABLE 1789 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY INJECTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1003 TABLE 1790 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY ORAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1004 TABLE 1791 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TOPICAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1004 TABLE 1792 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OCCULAR DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1005 TABLE 1793 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1005 TABLE 1794 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY NASAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1005 TABLE 1795 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY TRANSMUCOSAL DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1006 TABLE 1796 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY IMPLANTABLE DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1006 TABLE 1797 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY OTIC DRUG DELIVERY APPLICATION, 2024-2031 (USD BILLION) 1006 TABLE 1798 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY END USER, 2024-2031 (USD BILLION) 1007 TABLE 1799 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY FORMULATION END USER, 2024-2031 (USD BILLION) 1007 TABLE 1800 REST OF MIDDLE EAST & AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, BY PHARMACEUTICAL DRUG DELIVERY DEVICE END USER, 2024-2031 (USD BILLION) 1007 TABLE 1801 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET 1008 TABLE 1802 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS: DEGREE OF COMPETITION 1012 TABLE 1803 GLOBAL INJECTABLE DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1014 TABLE 1804 US INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION 1017 TABLE 1805 EUROPE INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION 1018 TABLE 1806 GLOBAL ORAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1019 TABLE 1807 US ORAL DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION 1020 TABLE 1808 EUROPE ORAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1021 TABLE 1809 GLOBAL TOPICAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1022 TABLE 1810 US TOPICAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1023 TABLE 1811 EUROPE TOPICAL DRUG DELIVERY MANUFACTURERS: DEGREE OF COMPETITION 1024 TABLE 1812 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: REGION FOOTPRINT 1030 TABLE 1813 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: PRODUCT TYPE FOOTPRINT 1030 TABLE 1814 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: USABILITY FOOTPRINT 1031 TABLE 1815 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS: REGION FOOTPRINT 1034 TABLE 1816 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS: ROUTE OF ADMINISTRATION FOOTPRINT 1035 TABLE 1817 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS: APPLICATION FOOTPRINT 1036 TABLE 1818 PHARMACEUTICAL DRUG DELIVERY MARKET: DETAILED LIST OF KEY INJECTABLE DRUG DELIVERY FORMULATION STARTUPS/SME PLAYERS 1039 TABLE 1819 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE BENCHMARKING OF PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES 1039 TABLE 1820 PHARMACEUTICAL DRUG DELIVERY MARKET: PRODUCT APPROVALS AND LAUNCHES, JANUARY 2022- APRIL 2026 1040 TABLE 1821 PHARMACEUTICAL DRUG DELIVERY MARKET: DEALS, JANUARY 2022- APRIL 2026 1041 TABLE 1822 PHARMACEUTICAL DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022–APRIL 2026 1042 TABLE 1823 PHARMACEUTICAL DRUG DELIVERY MARKET: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2026 1043 TABLE 1824 JOHNSON & JOHNSON: COMPANY OVERVIEW 1044 TABLE 1825 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 1045 TABLE 1826 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS, JANUARY 2022−APRIL 2026 1047 TABLE 1827 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022−APRIL 2026 1054 TABLE 1828 JOHNSON & JOHNSON: EXPANSIONS, JANUARY 2022−APRIL 2026 1056 TABLE 1829 JOHNSON & JOHNSON: OTHERS, JANUARY 2022−APRIL 2026 1056 TABLE 1830 NOVARTIS AG: COMPANY OVERVIEW 1058 TABLE 1831 NOVARTIS AG: PRODUCTS OFFERED 1059 TABLE 1832 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1062 TABLE 1833 NOVARTIS AG: DEALS, JANUARY 2022–APRIL 2026 1064 TABLE 1834 NOVARTIS AG: EXPANSIONS, JANUARY 2022–APRIL 2026 1066 TABLE 1835 NOVARTIS: OTHERS, JANUARY 2022−APRIL 2026 1067 TABLE 1836 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 1069 TABLE 1837 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 1070 TABLE 1838 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1072 TABLE 1839 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022−APRIL 2026 1077 TABLE 1840 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2022–APRIL 2026 1078 TABLE 1841 F. HOFFMANN-LA ROCHE LTD: OTHERS, JANUARY 2022−APRIL 2026 1079 TABLE 1842 PFIZER INC.: COMPANY OVERVIEW 1080 TABLE 1843 PFIZER INC.: PRODUCTS OFFERED 1081 TABLE 1844 PFIZER INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1087 TABLE 1845 PFIZER INC.: DEALS, JANUARY 2022–APRIL 2026 1090 TABLE 1846 ELI LILLY AND COMPANY: COMPANY OVERVIEW 1093 TABLE 1847 ELI LILLY AND COMPANY: PRODUCTS OFFERED 1094 TABLE 1848 ELI LILLY AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1095 TABLE 1849 ELI LILLY AND COMPANY: DEALS, JANUARY 2022−APRIL 2026 1098 TABLE 1850 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–APRIL 2026 1100 TABLE 1851 GSK PLC.: COMPANY OVERVIEW 1103 TABLE 1852 GSK PLC.: PRODUCTS OFFERED 1104 TABLE 1853 GSK PLC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1109 TABLE 1854 GSK PLC.: DEALS, JANUARY 2022–APRIL 2026 1112 TABLE 1855 GSK PLC.: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1115 TABLE 1856 ABBVIE INC.: COMPANY OVERVIEW 1116 TABLE 1857 ABBVIE INC.: PRODUCTS OFFERED 1117 TABLE 1858 ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2022— APRIL 2026 1121 TABLE 1859 ABBVIE INC.: DEALS, JANUARY 2022— APRIL 2026 1123 TABLE 1860 ABBVIE INC.: EXPANSION, JANUARY 2022- APRIL 2026 1126 TABLE 1861 ABBVIE, INC: OTHER DEVELOPMENTS, JANUARY 2022-APRIL 2026 1127 TABLE 1862 MERCK & CO., INC.: COMPANY OVERVIEW 1128 TABLE 1863 MERCK & CO., INC.: PRODUCTS OFFERED 1129 TABLE 1864 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1132 TABLE 1865 MERCK & CO., INC.: DEALS, JANUARY 2022–APRIL 2026 1137 TABLE 1866 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022–APRIL 2026 1140 TABLE 1867 MERCK & CO., INC: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1140 TABLE 1868 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW 1141 TABLE 1869 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED 1142 TABLE 1870 BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1145 TABLE 1871 BAUSCH HEALTH COMPANIES INC.: DEALS, JANUARY 2022–APRIL 2026 1146 TABLE 1872 BAYER AG: COMPANY OVERVIEW 1147 TABLE 1873 BAYER AG: PRODUCTS OFFERED 1148 TABLE 1874 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1150 TABLE 1875 BAYER AG: DEALS, JANUARY 2022–APRIL 2026 1155 TABLE 1876 BAYER AG: EXPANSIONS, JANUARY 2022–APRIL 2026 1157 TABLE 1877 BAYER AG: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1158 TABLE 1878 AMGEN INC.: COMPANY OVERVIEW 1159 TABLE 1879 AMGEN INC.: PRODUCTS OFFERED 1160 TABLE 1880 AMGEN INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1161 TABLE 1881 AMGEN INC.: DEALS, JANUARY 2022–APRIL 2026 1163 TABLE 1882 AMGEN INC.: EXPANSIONS, JANUARY 2022–APRIL 2026 1164 TABLE 1883 ASTRAZENECA: COMPANY OVERVIEW 1166 TABLE 1884 ASTRAZENECA: PRODUCTS OFFERED 1167 TABLE 1885 ASTRAZENECA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1170 TABLE 1886 ASTRAZENECA: DEALS, JANUARY 2022–APRIL 2026 1177 TABLE 1887 ASTRAZENECA: EXPANSIONS, JANUARY 2022–APRIL 2026 1178 TABLE 1888 ASTRAZENECA: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1179 TABLE 1889 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 1180 TABLE 1890 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 1181 TABLE 1891 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1182 TABLE 1892 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022−APRIL 2026 1183 TABLE 1893 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022−APRIL 2026 1186 TABLE 1894 RUSAN PHARMA LTD.: COMPANY OVERVIEW 1199 TABLE 1895 CMP PHARMA, INC.: COMPANY OVERVIEW 1200 TABLE 1896 XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 1201 TABLE 1897 ADHEXPHARMA: COMPANY OVERVIEW 1202 TABLE 1898 BD: COMPANY OVERVIEW 1203 TABLE 1899 BD: PRODUCTS OFFERED 1204 TABLE 1900 BD: DEALS, JANUARY 2022−APRIL 2026 1207 TABLE 1901 BD: EXPANSIONS, JANUARY 2022–APRIL 2026 1207 TABLE 1902 BD: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1208 TABLE 1903 CARDINAL HEALTH: COMPANY OVERVIEW 1209 TABLE 1904 CARDINAL HEALTH: PRODUCTS OFFERED 1210 TABLE 1905 CARDINAL HEALTH: EXPANSIONS, JANUARY 2022–APRIL 2026 1211 TABLE 1906 B. BRAUN SE: COMPANY OVERVIEW 1213 TABLE 1907 B. BRAUN SE: PRODUCTS OFFERED 1214 TABLE 1908 TERUMO CORPORATION: COMPANY OVERVIEW (2025) 1216 TABLE 1909 TERUMO CORPORATION: PRODUCTS OFFERED 1217 TABLE 1910 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1218 TABLE 1911 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–APRIL 2026 1219 TABLE 1912 NIPRO: COMPANY OVERVIEW 1220 TABLE 1913 NIPRO: PRODUCTS OFFERED 1221 TABLE 1914 NIPRO: EXPANSIONS, JANUARY 2022–MARCH 2025 1222 TABLE 1915 STEVANATO GROUP: COMPANY OVERVIEW 1223 TABLE 1916 STEVANATO GROUP: PRODUCTS OFFERED 1224 TABLE 1917 STEVANATO GROUP: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1225 TABLE 1918 STEVANATO: DEALS, JANUARY 2022–APRIL 2026 1225 TABLE 1919 STEVANATO: EXPANSIONS, JANUARY 2022–APRIL 2026 1226 TABLE 1920 STEVANATO GROUP: OTHER DEVELOPMENTS, JANUARY 2022−APRIL 2026 1227 TABLE 1921 GERRESHEIMER AG: COMPANY OVERVIEW 1228 TABLE 1922 GERRESHEIMER AG: PRODUCTS OFFERED 1229 TABLE 1923 GERRESHEIMER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1230 TABLE 1924 GERRESHEIMER AG: DEALS, JANUARY 2022-APRIL 2026 1231 TABLE 1925 GERRESHEIMER AG: EXPANSIONS, JANUARY 2022-APRIL 2026 1232 TABLE 1926 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 1233 TABLE 1927 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED 1234 TABLE 1928 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2026 1235 TABLE 1929 WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022–APRIL 2026 1235 TABLE 1930 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2022–APRIL 2026 1236 TABLE 1931 YPSOMED: BUSINESS OVERVIEW 1237 TABLE 1932 YPSOMED: PRODUCTS OFFERED 1238 TABLE 1933 YPSOMED: PRODUCT LAUNCHES, JANUARY 2022 – APRIL 2026 1239 TABLE 1934 YPSOMED: DEALS, JANUARY 2022−APRIL 2026 1239 TABLE 1935 YPSOMED: EXPANSIONS, JANUARY 2022−APRIL 2026 1241 TABLE 1936 SHL MEDICAL AG: COMPANY OVERVIEW 1242 TABLE 1937 SHL MEDICAL AG: PRODUCTS OFFERED 1242 TABLE 1938 SHL MEDICAL AG: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2026 1243 TABLE 1939 SHL MEDICAL AG: DEALS, JANUARY 2022–APRIL 2026 1244 TABLE 1940 SHL MEDICAL AG: EXPANSIONS, JANUARY 2022–APRIL 2026 1245 TABLE 1941 STUDY ASSUMPTIONS 1262 TABLE 1942 RISK ASSESSMENT ANALYSIS 1263 FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION 106 FIGURE 2 MARKET SCENARIO 111 FIGURE 3 GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, 2024–2031 112 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2020–2025 112 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF PHARMACEUTICAL DRUG DELIVERY MARKET 113 FIGURE 6 HIGH-GROWTH SEGMENTS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2026–2031 114 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PHARMACEUTICAL DRUG DELIVERY MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 115 FIGURE 8 INCREASING NEED FOR PHARMACEUTICAL DRUG DELIVERY PRODUCTS TO FUEL MARKET GROWTH 116 FIGURE 9 PHARMACEUTICAL DRUG DELIVERY SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 117 FIGURE 10 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING THE FORECAST PERIOD 118 FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 118 FIGURE 12 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 119 FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 120 FIGURE 14 BIOPHARMACEUTICAL R&D SPENDING (2020–2026) 127 FIGURE 15 PHARMACEUTICAL DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS 136 FIGURE 16 PHARMACEUTICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS 142 FIGURE 17 PHARMACEUTICAL DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS 143 FIGURE 18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 153 FIGURE 19 PHARMACEUTICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO 154 FIGURE 20 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2024–2032 166 FIGURE 21 PHARMACEUTICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2015–APRIL 2026) 181 FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2015–APRIL 2026) 182 FIGURE 23 AI USE CASES 185 FIGURE 24 KEY STAKEHOLDERS IN BUYING PROCESS FOR PHARMACEUTICAL DRUG DELIVERY DEVICES 197 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACEUTICAL DRUG DELIVERY FORMULATIONS 198 FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS 199 FIGURE 27 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT (2025) 465 FIGURE 28 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 468 FIGURE 29 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 681 FIGURE 30 REVENUE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS, 2023−2025 1010 FIGURE 31 REVENUE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2023−2025 1011 FIGURE 32 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1012 FIGURE 33 RANKING OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2025 1013 FIGURE 34 GLOBAL MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1014 FIGURE 35 RANKING OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1016 FIGURE 36 US MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1016 FIGURE 37 EUROPE MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1017 FIGURE 38 GLOBAL MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY MANUFACTURERS, 2025 1018 FIGURE 39 US MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY FORMULATION MANUFACTURERS, 2025 1019 FIGURE 40 EUROPE MARKET SHARE ANALYSIS OF ORAL DRUG DELIVERY MANUFACTURERS, 2025 1020 FIGURE 41 GLOBAL MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1021 FIGURE 42 US MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1022 FIGURE 43 EUROPE MARKET SHARE ANALYSIS OF TOPICAL DRUG DELIVERY MANUFACTURERS, 2025 1023 FIGURE 44 PHARMACEUTICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARISON 1025 FIGURE 45 R&D EXPENDITURE OF KEY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET, 2023−2025 1026 FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 1026 FIGURE 47 YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 1027 FIGURE 48 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS (2025) 1028 FIGURE 49 PHARMACEUTICAL DRUG DELIVERY DEVICE MANUFACTURERS: COMPANY FOOTPRINT 1029 FIGURE 50 COMPANY EVALUATION MATRIX: PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS (2025) 1032 FIGURE 51 PHARMACEUTICAL DRUG DELIVERY FORMULATION MANUFACTURERS: COMPANY FOOTPRINT 1033 FIGURE 52 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (PHARMACEUTICAL DRUG DELIVERY FORMULATION STARTUPS/SMES), 2025 1038 FIGURE 53 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2025) 1045 FIGURE 54 NOVARTIS AG: COMPANY SNAPSHOT (2025) 1059 FIGURE 55 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 1070 FIGURE 56 PFIZER INC.: COMPANY SNAPSHOT (2025) 1081 FIGURE 57 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025) 1094 FIGURE 58 GSK PLC.: COMPANY SNAPSHOT (2025) 1104 FIGURE 59 ABBVIE, INC.: COMPANY SNAPSHOT (2025) 1117 FIGURE 60 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 1129 FIGURE 61 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2025) 1142 FIGURE 62 BAYER AG: COMPANY SNAPSHOT (2025) 1148 FIGURE 63 AMGEN INC.: COMPANY SNAPSHOT (2025) 1160 FIGURE 64 ASTRAZENECA: COMPANY SNAPSHOT (2025) 1167 FIGURE 65 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025) 1181 FIGURE 66 BD: COMPANY SNAPSHOT (2025) 1204 FIGURE 67 CARDINAL HEALTH: COMPANY SNAPSHOT (2024) 1210 FIGURE 68 B. BRAUN SE: COMPANY SNAPSHOT (2025) 1214 FIGURE 69 TERUMO CORPORATION: COMPANY SNAPSHOT (2025) 1217 FIGURE 70 NIPRO: COMPANY SNAPSHOT (2025) 1221 FIGURE 71 STEVANATO GROUP: COMPANY SNAPSHOT (2025) 1224 FIGURE 72 GERRESHEIMER AG: COMPANY SNAPSHOT (2025) 1229 FIGURE 73 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2025) 1234 FIGURE 74 YPSOMED: COMPANY SNAPSHOT (2025) 1238 FIGURE 75 PHARMACEUTICAL DRUG DELIVERY MARKET: RESEARCH DESIGN 1246 FIGURE 76 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 1251 FIGURE 77 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 1252 FIGURE 78 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 1252 FIGURE 79 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 1253 FIGURE 80 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 1254 FIGURE 81 REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON (2025). 1255 FIGURE 82 TOP-DOWN APPROACH 1256 FIGURE 83 BOTTOM-UP APPROACH 1256 FIGURE 84 DEMAND-SIDE APPROACH 1257 FIGURE 85 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF PHARMACEUTICAL DRUG DELIVERY MARKET (2026–2031) 1258 FIGURE 86 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 1259 FIGURE 87 DATA TRIANGULATION METHODOLOGY

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們